Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Hepatitis

  Free Subscription


Articles published in J Viral Hepat

Retrieve available abstracts of 445 articles:
HTML format



Single Articles


    December 2024
  1. BERTOLETTI A
    The immune response in chronic HBV infection.
    J Viral Hepat. 2024;31 Suppl 2:43-55.
    PubMed     Abstract available


  2. VO-QUANG E, Lemoine M
    Global elimination of HBV: Is it really achievable?
    J Viral Hepat. 2024;31 Suppl 2.
    PubMed     Abstract available


  3. LIM YS
    Treatment decisions based on HBV DNA.
    J Viral Hepat. 2024;31 Suppl 2:36-42.
    PubMed     Abstract available


    November 2024
  4. PARK Y, Heo J, Kang D, Gwak GY, et al
    Impact of Maternal Hepatitis B Virus Infection on Congenital Heart Disease Risk in Offspring: A National Cohort Study.
    J Viral Hepat. 2024 Nov 26. doi: 10.1111/jvh.14036.
    PubMed     Abstract available


  5. ROSECRANS A, Harris R, Clair AS, Rice M, et al
    Challenges and Opportunities for Treating Hepatitis C Amongst People Who Use Drugs: Experience of an Integrated Mobile Clinic in Baltimore City.
    J Viral Hepat. 2024 Nov 26. doi: 10.1111/jvh.14038.
    PubMed     Abstract available


  6. YEW KC, Sim ASY, Hawkins R, Acharyya S, et al
    Real-World Evaluation of Point-of-Care Testing for Hepatitis C Antibodies: Navigating Hepatitis C Elimination Effort.
    J Viral Hepat. 2024 Nov 22. doi: 10.1111/jvh.14039.
    PubMed     Abstract available


  7. KASSA GM, Weldemariam AG, Abrahim SA, French CE, et al
    Seroprevalence of Hepatitis C in Ethiopia: First National Study Based on the 2016 Ethiopian Demographic and Health Survey.
    J Viral Hepat. 2024 Nov 21. doi: 10.1111/jvh.14037.
    PubMed     Abstract available


  8. FURL R, Scarsi KK, Sayles H, Anderson M, et al
    Preferences and Feasibility of Long-Acting Technologies for the Treatment of Hepatitis C Virus: A Survey of Patients in Diverse Low- and Middle-Income Countries.
    J Viral Hepat. 2024 Nov 15. doi: 10.1111/jvh.14031.
    PubMed     Abstract available


  9. ANDANI A, Mellou K, Dewda P, Eeuwijk J, et al
    Evolution and Impact of Hepatitis A Epidemiology in Europe-Systematic Literature Review of the Last 20 Years.
    J Viral Hepat. 2024 Nov 11. doi: 10.1111/jvh.14030.
    PubMed     Abstract available


  10. WONG GL
    Updated Guidelines for the Prevention and Management of Chronic Hepatitis B-World Health Organization 2024 Compared With China 2022 HBV Guidelines.
    J Viral Hepat. 2024 Nov 6. doi: 10.1111/jvh.14032.
    PubMed     Abstract available


  11. DIRKS M, Hennemann AK, Grosse GM, Beer A, et al
    Long-Term Follow-Up of Neuropsychiatric Symptoms After Sustained Virological Response to Interferon-Free and Interferon-Based Hepatitis C Virus Treatment.
    J Viral Hepat. 2024 Nov 6. doi: 10.1111/jvh.14033.
    PubMed     Abstract available


  12. DAS S, Sood V, Rastogi A, Agarwal N, et al
    Clinico-Pathological Spectrum of Hepatitis A Virus-Induced Autoimmune-Like Hepatitis in Children.
    J Viral Hepat. 2024 Nov 1. doi: 10.1111/jvh.14028.
    PubMed     Abstract available


    October 2024
  13. ETOORI D, Cococcia S, Srivastava A, Flanagan S, et al
    The Camden and Islington Viral Hepatitis Identification Tool (CIVHIT): Use of a Clinical Database Case-Finding Tool for Hepatitis B, Hepatitis C and HIV in Primary Care.
    J Viral Hepat. 2024 Oct 24. doi: 10.1111/jvh.14027.
    PubMed     Abstract available


  14. ALI I, Muhammad S, Naqvi SSZH, Wei L, et al
    Hepatitis B Virus-Associated Liver Carcinoma: The Role of Iron Metabolism and Its Modulation.
    J Viral Hepat. 2024 Oct 24. doi: 10.1111/jvh.14016.
    PubMed     Abstract available


  15. GINNANE JF, Scott N, Radley A, Dillon JF, et al
    Cost-Effectiveness of Treating Hepatitis C in Clients on Opioid Agonist Therapy in Community Pharmacies Compared to Primary Healthcare in Australia.
    J Viral Hepat. 2024 Oct 23. doi: 10.1111/jvh.14015.
    PubMed     Abstract available


  16. MARTIN MT, Hietpas AR, Novak JL, Deming P, et al
    A National Survey of Pharmacist Involvement in Hepatitis C Virus Management in the United States.
    J Viral Hepat. 2024 Oct 22. doi: 10.1111/jvh.14014.
    PubMed     Abstract available


  17. YI S, Wiesmann C, Truong D, Sharma S, et al
    Community Pop-Up Clinic: Cascade of Care and HCV Treatment of Vancouver's Inner-City PWID Populations.
    J Viral Hepat. 2024 Oct 19. doi: 10.1111/jvh.14023.
    PubMed     Abstract available


  18. OHLENDORF V, Wubbolding M, Honer Zu Siederdissen C, Bremer B, et al
    Limited Value of HBV-RNA for Relapse Prediction After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative Hepatitis B Patients.
    J Viral Hepat. 2024 Oct 19. doi: 10.1111/jvh.14026.
    PubMed     Abstract available


  19. SIMMONS R, Harris R, Lim AG, Leeman D, et al
    Estimating Prevalence and Number of People With Chronic Hepatitis B: A Multiplier Method Based on Public Health Surveillance Data in UK (2015-2021).
    J Viral Hepat. 2024 Oct 16. doi: 10.1111/jvh.14019.
    PubMed     Abstract available


  20. IWADARE T, Kimura T, Sugiura A, Okumura T, et al
    Thrombospondin 2 as a Predictive Biomarker for HCC in Hepatitis C Patients: A Longitudinal Study Following DAA Therapy.
    J Viral Hepat. 2024 Oct 15. doi: 10.1111/jvh.14025.
    PubMed     Abstract available


  21. BALIASHVILI D, Merabishvili T, Tskhomelidze I, Tsereteli M, et al
    Evaluation of Hepatitis C Virus Transmission Through Endoscopy Procedures in the Country of Georgia.
    J Viral Hepat. 2024 Oct 14. doi: 10.1111/jvh.14022.
    PubMed     Abstract available


  22. ZAKALASHVILI M, Surguladze S, Baliashvili D, Zarkua J, et al
    Evaluation of Knowledge, Attitudes and Practices for Hepatitis B Virus Infection Among Primary Healthcare Physicians in Georgia.
    J Viral Hepat. 2024 Oct 10. doi: 10.1111/jvh.14011.
    PubMed     Abstract available


  23. BUTT AA, Yan P, Iwnetu R, Malik AA, et al
    Hepatitis Delta Coinfection Rates and All-Cause Mortality Among Hepatitis B-Infected Veterans in the USA.
    J Viral Hepat. 2024 Oct 9. doi: 10.1111/jvh.14021.
    PubMed     Abstract available


  24. CHEN Y, Zhang X, Yan X, Wang L, et al
    A Programme of Hepatitis C Surveillance With Active Linkage to Care (HEAL) for Inpatients in Two Tertiary Hospitals in Jiangsu, China.
    J Viral Hepat. 2024 Oct 9. doi: 10.1111/jvh.14020.
    PubMed     Abstract available


  25. LU Z, Sun YM, Chen S, Meng T, et al
    Multiple Low-Level Viraemia Suggest Hindered Liver Fibrosis Regression in Chronic Hepatitis B Patients During Antiviral Therapy.
    J Viral Hepat. 2024 Oct 7. doi: 10.1111/jvh.14012.
    PubMed     Abstract available


  26. PHAW NA, Rayner D, Johnson A, Thompson C, et al
    Harm Minimisation and Other Preventative Measures Must Improve to Reduce Transmission of Hepatitis C in Prisons.
    J Viral Hepat. 2024 Oct 7. doi: 10.1111/jvh.14017.
    PubMed    


  27. BULDUKOGLU OC, Ocal S, Cekin AH
    Disparities in the Detection, Diagnosing and Treatment of Hepatitis B Among Females.
    J Viral Hepat. 2024 Oct 5. doi: 10.1111/jvh.14013.
    PubMed    


  28. WAN Y, Yin S, Wu C
    Reply: Regarding the Predictive Role of CXCL16 in Liver Inflammation in Chronic Hepatitis B Patients.
    J Viral Hepat. 2024 Oct 5. doi: 10.1111/jvh.13996.
    PubMed    


  29. ZHANG HL, Nemeth H, Woodhouse EW, Davenport CA, et al
    Prevalence of and Risk Factors for Liver Enzyme Elevation After Hepatitis C Virologic Cure.
    J Viral Hepat. 2024 Oct 3. doi: 10.1111/jvh.14009.
    PubMed     Abstract available


  30. PATEL P, Wells MT, Wethington E, Shapiro M, et al
    United States Provider Experiences With Telemedicine for Hepatitis C Treatment: A Nationwide Survey.
    J Viral Hepat. 2024 Oct 1. doi: 10.1111/jvh.14010.
    PubMed     Abstract available


  31. MAKUZA JD, Wong S, Morrow RL, Binka M, et al
    Impact of COVID-19 pandemic on hepatocellular carcinoma surveillance in British Columbia, Canada: An interrupted time series study.
    J Viral Hepat. 2024;31:592-600.
    PubMed     Abstract available


    September 2024
  32. TULENKO SE, Ngimbi P, Mwandagalirwa K, Tabala M, et al
    Immunogenicity of a Birth Dose of Hepatitis B Vaccine in Kinshasa, Democratic Republic of Congo: A Randomised, Controlled Trial.
    J Viral Hepat. 2024 Sep 24. doi: 10.1111/jvh.14003.
    PubMed     Abstract available


  33. ZOVICH B, Patel P, Tu T, Wang S, et al
    Perspectives of People Living With Chronic Hepatitis D: Impact of Disease and Unmet Needs Along the Care Cascade.
    J Viral Hepat. 2024 Sep 17. doi: 10.1111/jvh.14005.
    PubMed     Abstract available


  34. SONG Y, Chen H, Li J, Zhong F, et al
    Lower Serum Albumin Level: A Prospective Risk Predictor of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection.
    J Viral Hepat. 2024 Sep 16. doi: 10.1111/jvh.14008.
    PubMed     Abstract available


  35. LIANG LY, Yip TC, Lai JC, Lam AS, et al
    Dynamic Changes in ELF Score Predict Hepatocellular Carcinoma in Chronic Hepatitis B Patients Receiving Antiviral Treatment.
    J Viral Hepat. 2024 Sep 10. doi: 10.1111/jvh.14004.
    PubMed     Abstract available


  36. BARRE T, Parlati L, Bourliere M, Ramier C, et al
    Socioeconomic Deprivation Weighs Heavily on Liver Fibrosis and Mortality After Hepatitis C Cure (ANRS CO22 Hepather).
    J Viral Hepat. 2024 Sep 10. doi: 10.1111/jvh.14006.
    PubMed     Abstract available


  37. KWOK TY, Hui RW, Mao X, Ling GS, et al
    Cigarette Smoking Is Associated With Lower Chance of Hepatitis B Surface Antigen Seroclearance and Altered Host Immunity.
    J Viral Hepat. 2024 Sep 9. doi: 10.1111/jvh.14007.
    PubMed     Abstract available


  38. GRANTZ KH, Cepeda J, Astemborski J, Kirk GD, et al
    Individual Heterogeneity and Trends in Hepatitis C Infection Risk Among People Who Inject Drugs: A Longitudinal Analysis.
    J Viral Hepat. 2024 Sep 5. doi: 10.1111/jvh.13999.
    PubMed     Abstract available


  39. HOFMEISTER MG, Ly KN, Yin S, Spradling PR, et al
    Evolving Characteristics of Decedents With Hepatitis A Listed as a Cause of Death, United States, 2011-2021.
    J Viral Hepat. 2024 Sep 3. doi: 10.1111/jvh.14002.
    PubMed     Abstract available


    August 2024
  40. PAK K, Ibrahim B, Saab S
    Safety of Tenofovir Disoproxil Fumarate Among Breastfeeding Infants of Patients With Chronic Hepatitis B: A Systematic Review.
    J Viral Hepat. 2024 Aug 29. doi: 10.1111/jvh.14001.
    PubMed     Abstract available


  41. MAHAJAN A, Kharawala S, Desai S, Kendrick S, et al
    Association of Hepatitis B Surface Antigen Levels With Long-Term Complications in Chronic Hepatitis B Virus Infection: A Systematic Literature Review.
    J Viral Hepat. 2024 Aug 16. doi: 10.1111/jvh.13988.
    PubMed     Abstract available


  42. SACHAR Y, Congly SE, Burak KW, Manko A, et al
    Epidemiology, Treatment Patterns and Survival in Canadian Patients With Chronic Hepatitis B-Related Hepatocellular Carcinoma.
    J Viral Hepat. 2024 Aug 16. doi: 10.1111/jvh.13989.
    PubMed     Abstract available


  43. WEI B, Li H, Cheng M, Yang Y, et al
    NLRP3 Inflammasome Activation Mediates Hepatitis E Virus-Induced Neuroinflammation.
    J Viral Hepat. 2024 Aug 13. doi: 10.1111/jvh.13998.
    PubMed     Abstract available


  44. THORNTON KA, Deming PD, Archer GRD, Ceniceros JA, et al
    Expanding Hepatitis C Virus Treatment in the New Mexico State Prison System: Using the ECHO Model for Provider and Prison Peer Education.
    J Viral Hepat. 2024 Aug 13. doi: 10.1111/jvh.13997.
    PubMed     Abstract available


  45. IMSIROVIC H, Macphail G, Conway B, Fraser C, et al
    Mixed-Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis.
    J Viral Hepat. 2024 Aug 12. doi: 10.1111/jvh.13995.
    PubMed     Abstract available


  46. WASUWANICH P, Wen TS, Egerman RS, Karnsakul W, et al
    Epidemiology and Outcomes of Hepatitis E Virus-Associated Hospitalisations in the United States With a Focus on Pregnancy: A Nationwide Population Study, 1998-2020.
    J Viral Hepat. 2024 Aug 11. doi: 10.1111/jvh.13994.
    PubMed     Abstract available


  47. CAVIGLIA GP, Casalone E, Olivero A, Birolo G, et al
    MiRNome Profiling of Circulating Extracellular Vesicles in Patients With Chronic Hepatitis D Undergoing Pegylated Interferon Alpha Treatment.
    J Viral Hepat. 2024 Aug 11. doi: 10.1111/jvh.14000.
    PubMed     Abstract available


  48. EL EKIABY M, Tanaka J, van Drimmelen H, Allain JP, et al
    Infectivity of Hepatitis B Virus Surface Antigen-Positive Plasma With Undetectable HBV-DNA: Can HBsAg Screening Be Discontinued in Egyptian Blood Donors?
    J Viral Hepat. 2024 Aug 10. doi: 10.1111/jvh.13990.
    PubMed     Abstract available


  49. RUPASINGHE D, Choi JY, Kumarasamy N, Pujari S, et al
    Post-Diagnosis HCV RNA Testing Rates Prior to HCV Treatment Among People Living With HIV With HCV Antibody Positivity in the Asia-Pacific Region.
    J Viral Hepat. 2024 Aug 8. doi: 10.1111/jvh.13993.
    PubMed     Abstract available


  50. PATEL NH, Lucko A, Vachon A, Doucette KE, et al
    Assessment of HBV variants and novel viral and immune biomarkers in chronic hepatitis B patients with metabolic dysfunction associated steatotic liver disease.
    J Viral Hepat. 2024 Aug 7. doi: 10.1111/jvh.13979.
    PubMed     Abstract available


  51. HAMA SA, Sirwan R, Abubakr M, Ahmed GS, et al
    Clinical Prevalence of Hepatitis D Virus Among Hepatitis B Patients in Sulaymaniyah Governorate, Northern Iraq.
    J Viral Hepat. 2024 Aug 7. doi: 10.1111/jvh.13987.
    PubMed     Abstract available


  52. FLISIAK R, Zarebska-Michaluk D, Janczewska E, Parfieniuk-Kowerda A, et al
    Sustained Virological Response After Early Discontinuation of Hepatitis C Treatment.
    J Viral Hepat. 2024 Aug 7. doi: 10.1111/jvh.13991.
    PubMed     Abstract available


  53. WONG RJ, Liao M, Chen Y, Kwan M, et al
    Outcomes of a 1-Year Pilot Study Implementing Universal Hepatitis Delta Virus Testing Among Veterans With Chronic Hepatitis B.
    J Viral Hepat. 2024 Aug 5. doi: 10.1111/jvh.13992.
    PubMed     Abstract available


    July 2024
  54. YENDEWA GA, Salata RA, Olasehinde T, Mulindwa F, et al
    Self-reported hepatitis B testing among noninstitutionalized adults in the United States before the implementation of universal screening, 2013-2017: A nationwide population-based study.
    J Viral Hepat. 2024 Jul 30. doi: 10.1111/jvh.13985.
    PubMed     Abstract available


  55. STASI C, Pacifici M, Puglia M, Voller F, et al
    Severe acute hepatitis of unknown origin in children: Is it still a mystery? What role does adenovirus play?
    J Viral Hepat. 2024 Jul 29. doi: 10.1111/jvh.13978.
    PubMed     Abstract available


  56. TRAMONTI FANTOZZI MP, Ceccarelli L, Petri D, De Vita E, et al
    Hepatitis C epidemiology and treatment outcomes in Italy: Impact of the DAA era and the COVID-19 pandemic.
    J Viral Hepat. 2024 Jul 27. doi: 10.1111/jvh.13983.
    PubMed     Abstract available


  57. ALAMNEH TS, Walker JG, Lim AG, Alam E, et al
    Changes in the prevalence of hepatitis B and C viral infections in Sindh province, Pakistan: Findings from two sero-surveys in 2007 and 2019.
    J Viral Hepat. 2024 Jul 26. doi: 10.1111/jvh.13986.
    PubMed     Abstract available


  58. CHEN B, Iqbal U, Desai SK, Gries J, et al
    The role of treatment of hepatitis C with direct-acting antiviral agents on glycaemic control in diabetic patients: An updated systematic review and meta-analysis.
    J Viral Hepat. 2024 Jul 24. doi: 10.1111/jvh.13984.
    PubMed     Abstract available


  59. HUTTON DW, Toy M, Yang D, Zhang H, et al
    Modelling the potential impact of global hepatitis B vaccination on the burden of chronic hepatitis B in the United States.
    J Viral Hepat. 2024 Jul 22. doi: 10.1111/jvh.13982.
    PubMed     Abstract available


  60. BEYDOUN HA, Tsai J
    Screening rates for hepatitis B and C among low-income US veterans: Data from the National Veteran Homeless and Other Poverty Experiences Study.
    J Viral Hepat. 2024 Jul 10. doi: 10.1111/jvh.13981.
    PubMed     Abstract available


  61. HUANG D, Lai H, Zhu Z, Yu H, et al
    Inverse relationship between HBV DNA levels and liver histopathological changes in immune-tolerant CHB patients.
    J Viral Hepat. 2024;31:363-371.
    PubMed     Abstract available


    June 2024
  62. ZHANG J, Zhang Y
    Regarding the predictive role of CXCL16 in liver inflammation in chronic hepatitis B patients.
    J Viral Hepat. 2024 Jun 10. doi: 10.1111/jvh.13976.
    PubMed    


  63. LI T, Chen Y, Zhang Y, Wu S, et al
    Elevated hepatitis B virus RNA levels in HBeAg-positive patients with low-level viraemia or previous low-level viraemia.
    J Viral Hepat. 2024 Jun 10. doi: 10.1111/jvh.13957.
    PubMed     Abstract available


  64. COSTE M, Diouf A, Ndong C, Diouf A, et al
    Investigating linkage to care following community-based screening for hepatitis B virus in rural Senegal: A mixed methods study.
    J Viral Hepat. 2024 Jun 5. doi: 10.1111/jvh.13977.
    PubMed     Abstract available


  65. CLIPMAN SJ, Mehta SH, Mohapatra S, Srikrishnan AK, et al
    Network-based strategies to combat HCV: Examining social and spatial drivers of transmission among PWID in New Delhi.
    J Viral Hepat. 2024 Jun 4. doi: 10.1111/jvh.13960.
    PubMed     Abstract available


  66. MOUSAVI S, Alavi M, Delavari A, Poustchi H, et al
    Towards hepatitis C virus elimination in Iran: A blueprint for comprehensive strategies.
    J Viral Hepat. 2024 Jun 3. doi: 10.1111/jvh.13975.
    PubMed     Abstract available


    May 2024
  67. KHAN N, Kakakhel S, Malik A, Nigar K, et al
    Genetic substructure and host-specific natural selection trend across vaccine-candidate ORF-2 capsid protein of hepatitis-E virus.
    J Viral Hepat. 2024 May 28. doi: 10.1111/jvh.13959.
    PubMed     Abstract available


  68. DOWNS LO, Kabagambe K, Williams S, Waddilove E, et al
    Peer support for people living with hepatitis B virus-A foundation for treatment expansion.
    J Viral Hepat. 2024 May 26. doi: 10.1111/jvh.13952.
    PubMed     Abstract available


  69. SHAYAN NA, Rahimi A, Stranges S, Thind A, et al
    Factors affecting quality of life in hepatitis B patients in Herat, Afghanistan: A case-control study.
    J Viral Hepat. 2024 May 24. doi: 10.1111/jvh.13961.
    PubMed     Abstract available


  70. KOCHAKSARAEI GS, Yang F, Seow CH, Barkema HW, et al
    Epidemiology, linkage to care and natural history of women of childbearing age with chronic hepatitis B: A population-based study.
    J Viral Hepat. 2024 May 21. doi: 10.1111/jvh.13954.
    PubMed     Abstract available


  71. GU Q, Yin S, Tong X, Rui F, et al
    Current research insights into the role of CTLA-4 in hepatitis B virus (HBV) infection.
    J Viral Hepat. 2024 May 21. doi: 10.1111/jvh.13958.
    PubMed     Abstract available


  72. QURESHI H, Mahmood H, Nasir Z, Siddique S, et al
    A novel test and treat program for hepatitis C virus infection utilizing HCV core antigen testing, among police and general population, Islamabad, Pakistan, 2022.
    J Viral Hepat. 2024 May 21. doi: 10.1111/jvh.13953.
    PubMed     Abstract available


  73. LE GUILLOU-GUILLEMETTE H, Pivert A, ElBara A, Vall M, et al
    Prevalence, clinical and virological characteristics and short-term prognosis of hepatitis delta infection among patients with HIV/HBV in Nouakchott, Mauritania.
    J Viral Hepat. 2024 May 21. doi: 10.1111/jvh.13950.
    PubMed     Abstract available


  74. IRVIN R, Landry G, Jones MR, James A, et al
    High prevalence of hepatitis C virus infection among incarcerated persons: Results from the Louisiana Hepatitis C Elimination Plan's opt-out testing program in prisons.
    J Viral Hepat. 2024 May 17. doi: 10.1111/jvh.13941.
    PubMed     Abstract available


  75. MESZAROS M, Coursier S, Nagot N, Moulis L, et al
    Screening for hepatitis C virus at the time of mammography using rapid diagnostic tests in women aged between 50 and 74 years (Mamm'OC NCT05067374).
    J Viral Hepat. 2024 May 15. doi: 10.1111/jvh.13947.
    PubMed     Abstract available


  76. ROUSSOS S, Bagos C, Angelopoulos T, Chaikalis S, et al
    Incidence of primary hepatitis C infection among people who inject drugs during 2012-2020 in Athens, Greece.
    J Viral Hepat. 2024 May 14. doi: 10.1111/jvh.13951.
    PubMed     Abstract available


  77. ZHONG W, Zheng J, Yao N, Feng Y, et al
    Association of HBeAg decline rate from mid-pregnancy to delivery with HBeAg seroconversion after delivery in hepatitis B virus-infected mothers.
    J Viral Hepat. 2024 May 10. doi: 10.1111/jvh.13948.
    PubMed     Abstract available


  78. KUMAR A, Sahu U, Agnihotri G, Dixit A, et al
    A novel multi-epitope peptide vaccine candidate targeting hepatitis E virus: An in silico approach.
    J Viral Hepat. 2024 May 10. doi: 10.1111/jvh.13949.
    PubMed     Abstract available


  79. MAK LY, Yee LJ, Wong RJ, Ramers CB, et al
    Hepatocellular carcinoma among patients with chronic hepatitis B in the indeterminate phase.
    J Viral Hepat. 2024 May 8. doi: 10.1111/jvh.13914.
    PubMed     Abstract available


  80. RAZAVI-SHEARER D
    The economic argument for hepatitis B treatment simplification and expansion.
    J Viral Hepat. 2024 May 8. doi: 10.1111/jvh.13920.
    PubMed     Abstract available


    April 2024
  81. ALI M, Tucker JD, Kpokiri EE, Wu D, et al
    Crowdsourcing to increase hepatitis B and C testing and reduce hepatitis stigma among medical students in Bangladesh.
    J Viral Hepat. 2024 Apr 28. doi: 10.1111/jvh.13945.
    PubMed     Abstract available


  82. HOLT B, Mendoza J, Nguyen H, Doan D, et al
    Barriers and enablers to people-centred viral hepatitis care in Vietnam and the Philippines: Results of a patient journey mapping study.
    J Viral Hepat. 2024 Apr 23. doi: 10.1111/jvh.13944.
    PubMed     Abstract available


  83. ALQAHTANI SA, Yilmaz Y, El-Kassas M, Alswat K, et al
    Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt.
    J Viral Hepat. 2024 Apr 15. doi: 10.1111/jvh.13935.
    PubMed     Abstract available


  84. WONG RJ, Hirode G, Feld J, Wong SS, et al
    An updated assessment of hepatitis delta prevalence among adults in Canada: A meta-analysis.
    J Viral Hepat. 2024 Apr 15. doi: 10.1111/jvh.13939.
    PubMed     Abstract available


  85. OLTMANNS C, Bremer B, Kusche L, Stal P, et al
    Elevation of S2-bound alpha1-acid glycoprotein is associated with chronic hepatitis C virus infection and hepatocellular carcinoma.
    J Viral Hepat. 2024 Apr 12. doi: 10.1111/jvh.13943.
    PubMed     Abstract available


  86. RUI F, Garcia E, Hu X, Ni W, et al
    Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta-analysis.
    J Viral Hepat. 2024 Apr 8. doi: 10.1111/jvh.13942.
    PubMed     Abstract available


  87. SARAVANAN S, Shankar EM, Vignesh R, Ganesh PS, et al
    Occult hepatitis B virus infection and current perspectives on global WHO 2030 eradication.
    J Viral Hepat. 2024 Apr 5. doi: 10.1111/jvh.13928.
    PubMed     Abstract available


  88. MAINA A, Foster GR
    Hepatitis after gene therapy, what are the possible causes?
    J Viral Hepat. 2024;31 Suppl 1:14-20.
    PubMed     Abstract available


    March 2024
  89. GUPTA N, Swindells S, Scarsi KK, Furl R, et al
    Preferences and feasibility of long-acting technologies for treatment of hepatitis C virus in low- and middle-income countries: A survey of providers and policymakers.
    J Viral Hepat. 2024 Mar 28. doi: 10.1111/jvh.13921.
    PubMed     Abstract available


  90. NAVEED A, Khalid A, Janjua N, Cloherty GA, et al
    Performance of HCV core antigen and PCR testing in a predominantly genotype 3 population.
    J Viral Hepat. 2024 Mar 14. doi: 10.1111/jvh.13937.
    PubMed     Abstract available


  91. DOBROWOLSKA K, Pawlowska M, Zarebska-Michaluk D, Rzymski P, et al
    Direct-acting antivirals in women of reproductive age infected with hepatitis C virus.
    J Viral Hepat. 2024 Mar 14. doi: 10.1111/jvh.13936.
    PubMed     Abstract available


  92. HAVENS JR, Lofwall MR, Young AM, Staton M, et al
    Predictors of engagement in screening for a hepatitis C virus (HCV) treatment trial in a rural Appalachian community.
    J Viral Hepat. 2024 Mar 4. doi: 10.1111/jvh.13933.
    PubMed     Abstract available


  93. SULKOWSKI MS, Martinez A, Tyson GL, Scholz K, et al
    Leveraging opportunities for treatment/user simplicity (LOTUS): Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugs.
    J Viral Hepat. 2024 Mar 3. doi: 10.1111/jvh.13927.
    PubMed     Abstract available


    February 2024
  94. KATCHER JG, Klassen AC, Hann HW, Chang M, et al
    Racial discrimination, knowledge, and health outcomes: The mediating role of hepatitis B-related stigma among patients with chronic hepatitis B.
    J Viral Hepat. 2024 Feb 26. doi: 10.1111/jvh.13932.
    PubMed     Abstract available


  95. IQBAL HS, Gunaratne MP, Loeb TA, Pradeep A, et al
    High prevalence of hepatitis B virus among MSM living with HIV in India.
    J Viral Hepat. 2024 Feb 22. doi: 10.1111/jvh.13929.
    PubMed     Abstract available


  96. WOLFSON-STOFKO B, Hirode G, Vanderhoff A, Karkada J, et al
    Real-world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada.
    J Viral Hepat. 2024 Feb 22. doi: 10.1111/jvh.13931.
    PubMed     Abstract available


  97. FRYE K, Davis A, Darby R, McDaniel K, et al
    A contactless cure: Leveraging telehealth to improve hepatitis C treatment at a safety-net hospital.
    J Viral Hepat. 2024 Feb 18. doi: 10.1111/jvh.13913.
    PubMed     Abstract available


  98. WALTER LA, Prados M, Lloyd A, Sontheimer S, et al
    Birth cohort-specific consideration in an Emergency Department Hepatitis C Testing Programme: A description of age-related characteristics and outcomes.
    J Viral Hepat. 2024 Feb 17. doi: 10.1111/jvh.13930.
    PubMed     Abstract available


  99. TULLY DC, Power KA, Sarette J, Stopka TJ, et al
    Validation of dried blood spots for capturing hepatitis C virus diversity for genomic surveillance.
    J Viral Hepat. 2024 Feb 16. doi: 10.1111/jvh.13924.
    PubMed     Abstract available


  100. WU L, Yang Z, Zheng M
    Biogenesis of serum HBV RNA and clinical phenomena of serum HBV RNA in chronic hepatitis B patients before and after receiving nucleos(t)ide analogues therapy.
    J Viral Hepat. 2024 Feb 8. doi: 10.1111/jvh.13926.
    PubMed     Abstract available


  101. EPSTEIN RL, Buzzee B, White LF, Feld JJ, et al
    Test characteristics for combining non-invasive liver fibrosis staging modalities in individuals with Hepatitis C virus.
    J Viral Hepat. 2024 Feb 7. doi: 10.1111/jvh.13925.
    PubMed     Abstract available


  102. LV R, Lu Y, Xiang W, Meng M, et al
    Chronic viral hepatitis C micro-elimination program using telemedicine in Guigang city.
    J Viral Hepat. 2024 Feb 7. doi: 10.1111/jvh.13922.
    PubMed     Abstract available


    January 2024
  103. FARAG MS, van Campenhout MJH, Sonneveld MJ, Fung S, et al
    Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study).
    J Viral Hepat. 2024 Jan 19. doi: 10.1111/jvh.13918.
    PubMed     Abstract available


  104. POLLOCK TS, Robert CA, Seybold DJ, Hur M, et al
    Prevalence of hepatitis C among pregnant women in an Appalachian population.
    J Viral Hepat. 2024 Jan 18. doi: 10.1111/jvh.13911.
    PubMed     Abstract available


  105. QIN W, Shao L, Wang J, Zhang H, et al
    Persistence of antibodies 5 years after hepatitis B vaccination in preterm birth children: A retrospective cohort study using real-world data.
    J Viral Hepat. 2024 Jan 18. doi: 10.1111/jvh.13908.
    PubMed     Abstract available


  106. HIBBERT M, Simmons R, Sabin CA, Mandal S, et al
    Identifying missed opportunities for hepatitis C virus antenatal testing and diagnosis in England.
    J Viral Hepat. 2024 Jan 4. doi: 10.1111/jvh.13906.
    PubMed     Abstract available


  107. QURESHI H, Duran AC, Mahmood H, Sarwar Z, et al
    Context-dependent accuracy of the cobas plasma separation card for HCV RNA viral load measurement.
    J Viral Hepat. 2024 Jan 2. doi: 10.1111/jvh.13910.
    PubMed     Abstract available


  108. HIGE S, Aoki K, Nakamoto D, Flaherty JF, et al
    Real-world safety and effectiveness of tenofovir alamenamide for 144 weeks in Japanese patients with chronic hepatitis B.
    J Viral Hepat. 2024 Jan 1. doi: 10.1111/jvh.13912.
    PubMed     Abstract available


    December 2023
  109. ALQAHTANI SA, Stepanova M, Al Shabeeb R, Eberly KL, et al
    The impact of hepatitis B and C positive serologies on the outcomes of non-hepatic solid organ transplantation in the United States.
    J Viral Hepat. 2023 Dec 29. doi: 10.1111/jvh.13916.
    PubMed     Abstract available


  110. O'KEEFE D, Jacka D, Douglass C, Gunn J, et al
    Distribution of rapid HCV antibody self-test kits via needle/syringe dispensing machines: Implementation and evaluation of the Vend-C pilot study in Melbourne, Australia.
    J Viral Hepat. 2023 Dec 29. doi: 10.1111/jvh.13909.
    PubMed     Abstract available


  111. TOYODA H, Koshiyama Y, Yasuda S, Kumada T, et al
    Effect of previous infection with hepatitis B virus on the incidence of hepatocellular carcinoma after sustained virologic response in patients with chronic hepatitis C virus infection.
    J Viral Hepat. 2023 Dec 26. doi: 10.1111/jvh.13907.
    PubMed     Abstract available


  112. WAN Y, Mao M, Li M, Liu J, et al
    Serum CXCL16: A new predictor of liver inflammation in patients with chronic hepatitis B.
    J Viral Hepat. 2023 Dec 25. doi: 10.1111/jvh.13905.
    PubMed     Abstract available


  113. ZHOU S, Qi K, Bersoff-Matcha SJ, Mishra P, et al
    Sex-related difference analyses of efficacy and safety in clinical trials of direct-acting antivirals to treat chronic HCV genotype 1 and 3 infections.
    J Viral Hepat. 2023 Dec 19. doi: 10.1111/jvh.13901.
    PubMed     Abstract available


  114. YANG Q, Lin T, Zhao Y, Qiu Y, et al
    International disease burden of acute viral hepatitis among adolescents and young adults: An observational study.
    J Viral Hepat. 2023 Dec 8. doi: 10.1111/jvh.13903.
    PubMed     Abstract available


  115. WASUWANICH P, So JM, Rajborirug S, Karnsakul W, et al
    Hepatitis A hospitalisations in the United States and risk factors for inpatient mortality: A nationwide population study, 1998-2020.
    J Viral Hepat. 2023 Dec 8. doi: 10.1111/jvh.13902.
    PubMed     Abstract available


  116. RAZAVI H, Blach S, Bregenzer A, Bruggmann P, et al
    Assessing the hepatitis C epidemiology in Switzerland: It is not that trivial.
    J Viral Hepat. 2023 Dec 8. doi: 10.1111/jvh.13904.
    PubMed    


  117. NING Q, Yang T, Guo X, Huang Y, et al
    CHB patients with rtA181T-mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes.
    J Viral Hepat. 2023;30:951-958.
    PubMed     Abstract available


    November 2023
  118. O'SULLIVAN M, Jones AM, Mourad A, Haddadin Y, et al
    Excellent hepatitis C virus cure rates despite increasing complexity of people who use drugs: Integrated-Test-stage Treat study final outcomes.
    J Viral Hepat. 2023 Nov 28. doi: 10.1111/jvh.13897.
    PubMed     Abstract available


  119. DEMIREL A, Uraz S, Deniz Z, Daglilar E, et al
    Epidemiology of hepatitis D virus infection in Europe: Is it vanishing?
    J Viral Hepat. 2023 Nov 14. doi: 10.1111/jvh.13899.
    PubMed     Abstract available


  120. HAJARIZADEH B, Carson JM, Byrne M, Grebely J, et al
    Incidence of hepatitis C virus infection in the prison setting: The SToP-C study.
    J Viral Hepat. 2023 Nov 7. doi: 10.1111/jvh.13895.
    PubMed     Abstract available


  121. NATOUR RT, Midlej A, Mahajna E, Kopelman Y, et al
    Chronic hepatitis B beyond clinical burden: Psychosocial effects and impact on quality of life.
    J Viral Hepat. 2023 Nov 3. doi: 10.1111/jvh.13894.
    PubMed     Abstract available


  122. TRELOAR C, Rance J, Bryant J, Lafferty L, et al
    "There's too much power in this number. It's freaking the whole response out": the views of key informants on evidence and targets to achieve hepatitis C elimination goals in Australia.
    J Viral Hepat. 2023 Nov 2. doi: 10.1111/jvh.13896.
    PubMed     Abstract available


    October 2023
  123. MAK LY, Koffas A, Dolman GE, Saleh H, et al
    Role of HBsAg levels in guiding hepatitis B virus prophylaxis in pregnancy: Insights from a multi-ethnic cohort.
    J Viral Hepat. 2023 Oct 26. doi: 10.1111/jvh.13893.
    PubMed     Abstract available


  124. BERTISCH B, Schaetti C, Schmid P, Peter L, et al
    Chronic hepatitis C virus infections in Switzerland in 2020: Lower than expected and suggesting achievement of WHO elimination targets.
    J Viral Hepat. 2023 Oct 7. doi: 10.1111/jvh.13892.
    PubMed    


  125. VANWOLLEGHEM T, Armstrong PA, Buti M, FitzSimons D, et al
    The elimination of hepatitis D as a public health problem: Needs and challenges.
    J Viral Hepat. 2023 Oct 3. doi: 10.1111/jvh.13891.
    PubMed     Abstract available


  126. VIRTUDAZO MCC, Aquino JB, Arellano RNB, Fortes RA, et al
    The role of dried blood spot tests in the detection of hepatitis B infection: A systematic review.
    J Viral Hepat. 2023 Oct 3. doi: 10.1111/jvh.13890.
    PubMed     Abstract available


  127. BEGHIN J, Meier-Stephenson V
    Does hepatitis delta virus have a preference for hepatitis B virus genotype? A systematic review of the literature.
    J Viral Hepat. 2023 Oct 3. doi: 10.1111/jvh.13889.
    PubMed     Abstract available


    September 2023
  128. MA NZ, Dai W, Bao X, Bu ZQ, et al
    Effects of hepatitis B virus infection on the treatment outcomes following in vitro fertilization/intracytoplasmic sperm injection: An analysis of 21,999 first embryo transfer cycles.
    J Viral Hepat. 2023 Sep 23. doi: 10.1111/jvh.13878.
    PubMed     Abstract available


  129. EVANS KN, Vettese T, Wortley PM, Gandhi AP, et al
    HIV and HCV testing at clinical encounters among people who inject drugs, 2013-2018-Opportunities for increased testing and prevention.
    J Viral Hepat. 2023 Sep 19. doi: 10.1111/jvh.13877.
    PubMed     Abstract available


  130. HE H, Wu Y, Jia Z, Xu H, et al
    Risk-stratified approach by aMAP score for community population infected with hepatitis B and C to guide subsequent liver cancer screening practice: A cohort study with 10-year follow-up.
    J Viral Hepat. 2023 Sep 18. doi: 10.1111/jvh.13884.
    PubMed     Abstract available


  131. CAROLINE A, Kate M, Roberts M, Ryan J, et al
    What is the impact of a Hepatitis C 'test, trace and treat' pilot using peer workers?
    J Viral Hepat. 2023 Sep 18. doi: 10.1111/jvh.13888.
    PubMed     Abstract available


  132. JOHNSON A, Shearer J, Thompson C, Jelley R, et al
    Impact of 5 years of hepatitis C testing and treatment in the North East of England prisons.
    J Viral Hepat. 2023 Sep 12. doi: 10.1111/jvh.13887.
    PubMed     Abstract available


  133. KHAN S, Kumar Y, Sharma C, Gupta SK, et al
    Dysregulated metabolites and lipids in serum of patients with acute hepatitis E: A longitudinal study.
    J Viral Hepat. 2023 Sep 11. doi: 10.1111/jvh.13885.
    PubMed     Abstract available


    August 2023
  134. ZHANG R, Liu H, Lin J, Ding J, et al
    AhR may be involved in Th17 cell differentiation in chronic hepatitis B.
    J Viral Hepat. 2023 Aug 23. doi: 10.1111/jvh.13883.
    PubMed     Abstract available


  135. SHAH SHBU, Valerio H, Hajarizadeh B, Matthews G, et al
    Cascade of care among people with hepatitis B in New South Wales, Australia.
    J Viral Hepat. 2023 Aug 8. doi: 10.1111/jvh.13881.
    PubMed     Abstract available


  136. BLACH S, Bregenzer A, Bruggmann P, Cerny A, et al
    Assessing the hepatitis C epidemiology in Switzerland: it's not that trivial.
    J Viral Hepat. 2023 Aug 8. doi: 10.1111/jvh.13879.
    PubMed    


  137. ZHOU R, Yang L, Zhang B, Gu Y, et al
    Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: A systematic review and meta-analysis.
    J Viral Hepat. 2023 Aug 2. doi: 10.1111/jvh.13872.
    PubMed     Abstract available


  138. VASSILOPOULOS S, Kalligeros M, Vassilopoulos A, Shehadeh F, et al
    Impact of prior HBV, HAV, and HEV infection on non-alcoholic fatty liver disease.
    J Viral Hepat. 2023;30:685-693.
    PubMed     Abstract available


    July 2023
  139. PAUL SS, Patwa SM, Tan YJ
    Development of monoclonal antibodies to target the large surface protein of hepatitis B virus and their use in therapeutic and diagnostic applications.
    J Viral Hepat. 2023 Jul 31. doi: 10.1111/jvh.13880.
    PubMed     Abstract available


  140. GAN QY, Wang JX, Qian F, Wang YL, et al
    Clinical and histological features of patients with chronic hepatitis B virus infection in the grey zone.
    J Viral Hepat. 2023 Jul 26. doi: 10.1111/jvh.13873.
    PubMed     Abstract available


  141. FERRANTE ND, Kallan MJ, Sukkestad S, Kodani M, et al
    Prevalence and determinants of hepatitis delta virus infection among HIV/hepatitis B-coinfected adults in care in the United States.
    J Viral Hepat. 2023 Jul 24. doi: 10.1111/jvh.13874.
    PubMed     Abstract available


  142. PERAZZO H, Castro R, Villela-Nogueira C, Torres M, et al
    Acceptability and usability of oral fluid HCV self-testing for hepatitis C diagnosis: A systematic review and meta-analysis.
    J Viral Hepat. 2023 Jul 23. doi: 10.1111/jvh.13876.
    PubMed     Abstract available


  143. TORRES C, Bauer G, Aubriet S, Scholtes C, et al
    Profile of patients with a positive HCV viral load in a large French psychiatric hospital (2019-2021): A case-control study.
    J Viral Hepat. 2023 Jul 23. doi: 10.1111/jvh.13875.
    PubMed     Abstract available


  144. ROSSOTTI R
    Substance use and CD4/CD8 ratio in HIV/HCV co-infected people receiving direct-acting antiviral treatment (ANRS CO13 HEPAVIH): Authors' reply.
    J Viral Hepat. 2023 Jul 11. doi: 10.1111/jvh.13871.
    PubMed    


  145. LU M, Salgia R, Li J, Trudeau S, et al
    Dynamic risk assessment for hepatocellular carcinoma in patients with chronic hepatitis C.
    J Viral Hepat. 2023 Jul 6. doi: 10.1111/jvh.13859.
    PubMed     Abstract available


  146. GARCIA A, Vigil KJ, Taylor B, Kshirsagar O, et al
    Persistent low prevalence of hepatitis B vaccination among people with HIV: Time for a change?
    J Viral Hepat. 2023 Jul 4. doi: 10.1111/jvh.13868.
    PubMed     Abstract available


    June 2023
  147. COYLE CR, Desjardins MR, Curriero FC, Rudolph J, et al
    Geographic variation in HCV treatment penetration among people who inject drugs in Baltimore, MD.
    J Viral Hepat. 2023 Jun 29. doi: 10.1111/jvh.13864.
    PubMed     Abstract available


  148. GORDON SC, Kaushik A, Chastek B, Anderson A, et al
    Characteristics associated with receipt of treatment among patients diagnosed with chronic hepatitis C virus.
    J Viral Hepat. 2023 Jun 28. doi: 10.1111/jvh.13860.
    PubMed     Abstract available


  149. OKUMURA T, Joshita S, Iwadare T, Wakabayashi SI, et al
    Kinetics of serum O-glycosylated M-hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patients.
    J Viral Hepat. 2023 Jun 26. doi: 10.1111/jvh.13869.
    PubMed     Abstract available


  150. BARRE T, Zucman D, Marcellin F, Ramier C, et al
    Substance use and CD4/CD8 ratio in HIV/HCV co-infected people receiving direct-acting antiviral treatment (ANRS CO13 HEPAVIH).
    J Viral Hepat. 2023 Jun 26. doi: 10.1111/jvh.13865.
    PubMed    


  151. JOHNSTON JM, McMahon B, Simons BC, Homan C, et al
    Comparison of HBV DNA and RNA markers in Alaska native people who did and did not clear hepatitis B surface antigen.
    J Viral Hepat. 2023 Jun 22. doi: 10.1111/jvh.13867.
    PubMed     Abstract available


  152. KONDILI LA, Craxi A
    Migrants and hepatitis: A tale of two worlds.
    J Viral Hepat. 2023 Jun 21. doi: 10.1111/jvh.13866.
    PubMed    


  153. TRICKEY A, Ingle SM, Boyd A, Gill MJ, et al
    Contribution of alcohol use in HIV/hepatitis C virus co-infection to all-cause and cause-specific mortality: A collaboration of cohort studies.
    J Viral Hepat. 2023 Jun 20. doi: 10.1111/jvh.13863.
    PubMed     Abstract available


  154. LEOW YW, Chan WK
    Response to letter to editor: Potential impact of Helicobacter pylori infection on hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B.
    J Viral Hepat. 2023 Jun 20. doi: 10.1111/jvh.13858.
    PubMed    


  155. HOVAGUIMIAN F, Beeler PE, Mullhaupt B, Gunthard HF, et al
    Mortality and morbidity related to hepatitis C virus infection in hospitalized adults-A propensity score matched analysis.
    J Viral Hepat. 2023 Jun 12. doi: 10.1111/jvh.13861.
    PubMed     Abstract available


  156. BERTISCH B, Schaetti C, Schmid P, Peter L, et al
    Chronic hepatitis C virus infections in Switzerland in 2020: Lower than expected and suggesting achievement of WHO elimination targets.
    J Viral Hepat. 2023 Jun 6. doi: 10.1111/jvh.13842.
    PubMed     Abstract available


  157. LISKER-MELMAN M, King WC, Ghany MG, Chung RT, et al
    Human immunodeficiency virus coinfection differentially impacts hepatitis B virus viral markers based on hepatitis be antigen status in patients with suppressed viremia.
    J Viral Hepat. 2023 Jun 6. doi: 10.1111/jvh.13857.
    PubMed     Abstract available


  158. RAZAVI-SHEARER D, Estes C, Gamkrelidze I, Razavi H, et al
    Cost-effectiveness of treating all hepatitis B-positive individuals in the United States.
    J Viral Hepat. 2023 Jun 1. doi: 10.1111/jvh.13843.
    PubMed     Abstract available


  159. DE A, Charak S, Bhagat N, Rathi S, et al
    Efficacy and safety of pan-genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir-based antiretroviral therapy.
    J Viral Hepat. 2023 Jun 1. doi: 10.1111/jvh.13844.
    PubMed     Abstract available


  160. MUTIMER D, Elsharkawy A, Hathorn E, Arunkumar S, et al
    Rate and determinants of antiviral treatment initiation for patients with HBeAg-negative chronic hepatitis B.
    J Viral Hepat. 2023 Jun 1. doi: 10.1111/jvh.13841.
    PubMed     Abstract available


    May 2023
  161. KOUNTOURAS J, Papaefthymiou A, Polyzos SA, Kazakos E, et al
    Potential impact of Helicobacter pylori infection on hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B.
    J Viral Hepat. 2023 May 3. doi: 10.1111/jvh.13836.
    PubMed    


  162. ADDA D, Wang S
    A declaration from people living with hepatitis B: A call for a whole person approach.
    J Viral Hepat. 2023 May 2. doi: 10.1111/jvh.13839.
    PubMed    


  163. ZHOU J, He X, Ou Y, Peng S, et al
    Role of CXCR5(+) CD8(+) T cells in human hepatitis B virus infection.
    J Viral Hepat. 2023 May 2. doi: 10.1111/jvh.13840.
    PubMed     Abstract available


  164. JACOBSON IM, Bourgeois S, Mathurin P, Thuluvath P, et al
    The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis.
    J Viral Hepat. 2023;30:448-454.
    PubMed     Abstract available


  165. ZHANG W, Xing M, Sun W, Chen J, et al
    Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: A real-world analysis.
    J Viral Hepat. 2023;30:427-436.
    PubMed     Abstract available


    April 2023
  166. YENDEWA GA, Sellu EJ, Kpaka RA, James PB, et al
    Measuring stigma associated with hepatitis B virus infection in Sierra Leone: Validation of an abridged Berger HIV stigma scale.
    J Viral Hepat. 2023 Apr 21. doi: 10.1111/jvh.13838.
    PubMed     Abstract available


  167. PASSOS-CASTILHO AM, Murphy DG, Blouin K, Benedetti A, et al
    A population-based study of reported hepatitis C diagnoses from 1998 to 2018 in immigrants and nonimmigrants in Quebec, Canada.
    J Viral Hepat. 2023 Apr 18. doi: 10.1111/jvh.13837.
    PubMed     Abstract available


  168. SANDMANN L, Deterding K, Bremer B, Port K, et al
    Kinetics and predictive value of HBcrAg, HBV RNA and anti-HBc during bulevirtide treatment of chronic HDV-infected patients.
    J Viral Hepat. 2023;30:283-286.
    PubMed     Abstract available


    March 2023
  169. HIBBERT M, Simmons R, Harris H, Desai M, et al
    Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England.
    J Viral Hepat. 2023 Mar 17. doi: 10.1111/jvh.13835.
    PubMed     Abstract available


  170. DETERDING K, Xu CJ, Port K, Dietz-Fricke C, et al
    Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA.
    J Viral Hepat. 2023 Mar 16. doi: 10.1111/jvh.13831.
    PubMed     Abstract available


  171. URAZ S, Deniz Z, Zerdali EY, Araslanova A, et al
    The Changing Epidemiology of Delta Hepatitis in Turkiye over Three Decades: A Systematic Review.
    J Viral Hepat. 2023 Mar 15. doi: 10.1111/jvh.13834.
    PubMed     Abstract available


  172. WU C, Xie J, Liu F
    Incidence and factors influencing sleep disorders in patients with chronic hepatitis B infection: A case-control study.
    J Viral Hepat. 2023 Mar 15. doi: 10.1111/jvh.13832.
    PubMed     Abstract available


  173. MOREAU C, Roux M, Riou J, Canivet CM, et al
    Dynamic Personalized Prediction of the Individual Liver-Related Risk after Sustained Viral Response in HCV patients.
    J Viral Hepat. 2023 Mar 9. doi: 10.1111/jvh.13830.
    PubMed     Abstract available


  174. QIU L, Xu S, Qiu Y, Liu Y, et al
    Comparison of acknowledged hepatocellular carcinoma risk scores in high risk hepatitis C patients with sustained virologic response.
    J Viral Hepat. 2023 Mar 8. doi: 10.1111/jvh.13829.
    PubMed     Abstract available


  175. MOONEYHAN E, De la Torre Rosas A, Serrano DB, Gamkrelidze I, et al
    Cost-effectiveness and economic investment to eliminate chronic hepatitis C in Mexico.
    J Viral Hepat. 2023 Mar 8. doi: 10.1111/jvh.13828.
    PubMed     Abstract available


  176. SELIM R, Zhou Y, Gordon SC, Zhang T, et al
    Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct-acting antivirals.
    J Viral Hepat. 2023 Mar 5. doi: 10.1111/jvh.13826.
    PubMed     Abstract available


  177. ISAEVA OV, Kyuregyan KK, Karlsen AA, Kuzmin OV, et al
    Silent HDV epidemics culminates in high levels of liver cirrhosis in endemic region despite 20 years of HBV vaccination.
    J Viral Hepat. 2023;30:182-194.
    PubMed     Abstract available


  178. SULKOWSKI MS
    Hepatitis D virus infection: Progress on the path toward disease control and cure.
    J Viral Hepat. 2023 Mar 1. doi: 10.1111/jvh.13825.
    PubMed    


    February 2023
  179. SHAH SHBU, Alavi M, Hajarizadeh B, Matthews G, et al
    Liver-related mortality among people with hepatitis B and C: evaluation of definitions based on linked healthcare administrative datasets.
    J Viral Hepat. 2023 Feb 27. doi: 10.1111/jvh.13824.
    PubMed     Abstract available


  180. WONG RJ, Rupp L, Lu M, Yang Z, et al
    Prevalence of Hepatitis B Virus (HBV) and Latent Tuberculosis Co-Infection and Risk of Drug-Induced Liver Injury Across Two Large HBV Cohorts in the United States.
    J Viral Hepat. 2023 Feb 26. doi: 10.1111/jvh.13823.
    PubMed     Abstract available


  181. ANDANI A, Bunge E, Kassianos G, Eeuwijk J, et al
    Hepatitis A Occurrence and Outbreaks in Europe Over the Past Two Decades: a Systematic Review.
    J Viral Hepat. 2023 Feb 24. doi: 10.1111/jvh.13821.
    PubMed     Abstract available


  182. MICAELA M, Elizalde MM, Giadans C, Monzani C, et al
    Different mutation rates in the basal core promoter and precore regions between hepatitis B virus subgenotype F1b clusters.
    J Viral Hepat. 2023 Feb 24. doi: 10.1111/jvh.13822.
    PubMed    


  183. BRITO WI, Oliveira RM, Silva J, Tubarao LN, et al
    Persistence of immunity against hepatitis A in Brazilian children vaccinated with a single dose of inactivated virus vaccine.
    J Viral Hepat. 2023 Feb 20. doi: 10.1111/jvh.13819.
    PubMed     Abstract available


  184. ZHOU Y, Zhao B, Shi W, Ding X, et al
    The infection rates of HBV and HCV decreased significantly in Zhejiang Province, China: a comparative study based on the data of two sero-epidemiological surveys in 1992 and 2020.
    J Viral Hepat. 2023 Feb 20. doi: 10.1111/jvh.13820.
    PubMed     Abstract available


  185. ROSSOTTI R, Merli M, Baiguera C, Bana NB, et al
    Impact of treatment with direct-acting antivirals on inflammatory markers and autoantibodies in HIV/HCV co-infected individuals.
    J Viral Hepat. 2023 Feb 11. doi: 10.1111/jvh.13818.
    PubMed     Abstract available


  186. SUN F, Wei X, Yaoling O
    Research progress on detection methods for hepatitis B virus covalently closed circular DNA.
    J Viral Hepat. 2023 Feb 8. doi: 10.1111/jvh.13817.
    PubMed     Abstract available


  187. HAMILTON EM, Rassam W, Yan Y, Singh A, et al
    Correlates of chronic hepatitis B virus infection in the general adult population of China: systematic review and meta-analysis.
    J Viral Hepat. 2023 Feb 8. doi: 10.1111/jvh.13816.
    PubMed     Abstract available


  188. NYAMA ET, Allan-Blitz LT, Bitwayiki R, Swaray M, et al
    Challenges of Hepatitis B Treatment in Rural Sub-Saharan Africa: Treatment Initiation and Outcomes from a Public Hospital-Based Clinic in Kono, Sierra Leone.
    J Viral Hepat. 2023 Feb 5. doi: 10.1111/jvh.13812.
    PubMed     Abstract available


  189. FERRAIOLI G
    Interpreting shear wave elastography results in chronic hepatitis D virus infection.
    J Viral Hepat. 2023 Feb 5. doi: 10.1111/jvh.13815.
    PubMed    


  190. YARDENI D, Yang AH, Heller T, Koh C, et al
    Reply to "Interpreting shear wave elastography results in chronic hepatitis D virus infection".
    J Viral Hepat. 2023 Feb 5. doi: 10.1111/jvh.13813.
    PubMed    


  191. DEGASPERI E, Anolli MP, Lampertico P
    Bulevirtide-based treatment strategies for chronic hepatitis delta: A review.
    J Viral Hepat. 2023 Feb 5. doi: 10.1111/jvh.13811.
    PubMed     Abstract available


    January 2023
  192. FEI Y, Wang Z, Huang M, Wu X, et al
    MiR-155 regulates M2 polarization of hepatitis B virus-infected tumor-associated macrophages which in turn regulates malignant progression of hepatocellular carcinoma.
    J Viral Hepat. 2023 Jan 26. doi: 10.1111/jvh.13809.
    PubMed     Abstract available


  193. WANG J, Huang R, Liu J, Lai R, et al
    A novel non-invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD.
    J Viral Hepat. 2023 Jan 25. doi: 10.1111/jvh.13808.
    PubMed     Abstract available


  194. TERRAULT NA, Slepin J, Kanner R, Gailloux K, et al
    Strategies to Increase Primary Care Provider Capacity for Hepatitis C Care: The California ECHO-PLUS Study.
    J Viral Hepat. 2023 Jan 25. doi: 10.1111/jvh.13807.
    PubMed     Abstract available


  195. LIAN M, Wang Q, Chen S, Yang Y, et al
    The association of serum immunoglobulin and complement levels and liver fibrosis and inflammation stage in patients with chronic hepatitis B.
    J Viral Hepat. 2023 Jan 25. doi: 10.1111/jvh.13810.
    PubMed     Abstract available


  196. HUDSON-BUHAGIAR J, Carson J, Monaghan S, Collie P, et al
    Effectiveness of direct-acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: a national real-world cohort (REACH-C).
    J Viral Hepat. 2023 Jan 18. doi: 10.1111/jvh.13803.
    PubMed     Abstract available


  197. KALKAN C, Yilmaz Y, Doganay Erdogan B, Savas B, et al
    Non-invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta.
    J Viral Hepat. 2023 Jan 18. doi: 10.1111/jvh.13806.
    PubMed     Abstract available


  198. MOONEYHAN E, Qureshi H, Mahmood H, Tariq M, et al
    Hepatitis C prevalence and elimination planning in Pakistan, a bottom-up approach accounting for provincial variation.
    J Viral Hepat. 2023 Jan 17. doi: 10.1111/jvh.13802.
    PubMed     Abstract available


  199. KEITOKU T, Tamaki N, Kurosaki M, Inada K, et al
    Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapy.
    J Viral Hepat. 2023 Jan 17. doi: 10.1111/jvh.13805.
    PubMed     Abstract available


  200. MCKEEVER A, O'Donovan D, Kee F
    Factors influencing compliance with Hepatitis C treatment in patients transitioning from prison to community - a Summary Scoping Review.
    J Viral Hepat. 2023 Jan 12. doi: 10.1111/jvh.13801.
    PubMed     Abstract available


  201. KUSHNER T
    Delta Hepatitis Epidemiology and the Global Burden of Disease.
    J Viral Hepat. 2023 Jan 10. doi: 10.1111/jvh.13797.
    PubMed    


  202. LEOW YW, Chan WK, Goh GB, Wong VW, et al
    Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: the multicentre, prospective CAP-Asia study.
    J Viral Hepat. 2023 Jan 6. doi: 10.1111/jvh.13796.
    PubMed     Abstract available


  203. YOUNOSSI ZM, Yu ML, Yilmaz Y, Alswat KA, et al
    Clinical and Patient-Reported Outcome Profile of Patients with Hepatitis B Viral Infection from the Global Liver Registry.
    J Viral Hepat. 2023 Jan 4. doi: 10.1111/jvh.13800.
    PubMed     Abstract available


  204. DEBETTE-GRATIEN M, Francois S, Chevalier C, Alain S, et al
    Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days.
    J Viral Hepat. 2023 Jan 3. doi: 10.1111/jvh.13798.
    PubMed     Abstract available


    December 2022
  205. KOZUKA R, Tamori A, Enomoto M, Muto-Yukawa Y, et al
    Risk Factors for Liver-Related and Non-Liver-Related Mortality following a Sustained Virological Response after Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in a Real-World Cohort.
    J Viral Hepat. 2022 Dec 30. doi: 10.1111/jvh.13795.
    PubMed     Abstract available


  206. UCHIDA T, Yuji T, Imamura M, Abe-Chayama H, et al
    A novel cDNA-uPA/SCID/Rag2(-/-) /Jak3(-/-) mouse model for hepatitis virus infection and reconstruction of human immune system.
    J Viral Hepat. 2022 Dec 27. doi: 10.1111/jvh.13793.
    PubMed     Abstract available


  207. YOUSAFZAI MT, Alavi M, Valerio H, Hajarizadeh B, et al
    Hepatitis C care cascade before and during the direct acting antiviral eras in New South Wales, Australia: a population-based linkage study.
    J Viral Hepat. 2022 Dec 19. doi: 10.1111/jvh.13791.
    PubMed     Abstract available


  208. BIAN D, Zhao J, Liao H, Wang Y, et al
    Serum HBV RNA is Associated with Liver Fibrosis Regression in HBeAg-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogues.
    J Viral Hepat. 2022 Dec 19. doi: 10.1111/jvh.13790.
    PubMed     Abstract available


  209. SIEGELE-BROWN C, Siegele-Brown M, Cook C, Khakoo SI, et al
    Testing to sustain Hepatitis C elimination targets in people who inject drugs: a network-based model.
    J Viral Hepat. 2022 Dec 18. doi: 10.1111/jvh.13786.
    PubMed     Abstract available


  210. CAO X, Hu Q, Xu W, Li Q, et al
    Kinetics changes in total cholesterol predict HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon-alfa.
    J Viral Hepat. 2022 Dec 18. doi: 10.1111/jvh.13787.
    PubMed     Abstract available


  211. LAM L, Fontaine H, Lapidus N, Bellet J, et al
    Performance of Algorithms for Identifying Patients With Chronic Hepatitis B or C Infection in the French Health Insurance Claims Databases Using the ANRS CO22 HEPATHER Cohort.
    J Viral Hepat. 2022 Dec 18. doi: 10.1111/jvh.13788.
    PubMed     Abstract available


  212. GILL US
    The immune landscape in Hepatitis Delta Virus Infection - still an open field!
    J Viral Hepat. 2022 Dec 18. doi: 10.1111/jvh.13785.
    PubMed     Abstract available


  213. TARIK A
    Beyond bulevirtide: Alternative therapeutic options for the management of hepatitis delta virus.
    J Viral Hepat. 2022 Dec 18. doi: 10.1111/jvh.13789.
    PubMed     Abstract available


  214. CHAK EW, Luna R, MacDonald S, Stewart SL, et al
    Automated Electronic Health Registry-Based Hepatitis B Screening.
    J Viral Hepat. 2022 Dec 14. doi: 10.1111/jvh.13784.
    PubMed     Abstract available


  215. SARACCO M, Tandoi F, Maletta F, Balagna R, et al
    Early post-liver transplant use of direct-acting antivirals in naive and NS5A inhibitor-experienced HCV patients.
    J Viral Hepat. 2022 Dec 7. doi: 10.1111/jvh.13782.
    PubMed     Abstract available


  216. ROHRIG AM, Jakobi K, Dietz J, Thomas D, et al
    The Role of Serum Sphingolipids as potential biomarkers of non-response to Direct Acting Antiviral-Therapy in Chronic Hepatitis C Virus Infection.
    J Viral Hepat. 2022 Dec 4. doi: 10.1111/jvh.13776.
    PubMed     Abstract available


  217. GREENWALD ZR, Bouck Z, McLean E, Mason K, et al
    Integrated supervised consumption services and hepatitis C testing and treatment among people who inject drugs in Toronto, Canada: a cross-sectional analysis.
    J Viral Hepat. 2022 Dec 3. doi: 10.1111/jvh.13780.
    PubMed     Abstract available


  218. NATHANI R, Leibowitz R, Giri D, Villarroel C, et al
    The Delta Delta: Gaps in Screening and Patient Assessment for Hepatitis D Virus Infection.
    J Viral Hepat. 2022 Dec 2. doi: 10.1111/jvh.13779.
    PubMed     Abstract available


  219. MUTIMER D, Elsharkawy A, Hathorn E, Arunkumar S, et al
    Age, ethnicity and proximity to clinic determine retention in care of chronic hepatitis B patients.
    J Viral Hepat. 2022 Dec 2. doi: 10.1111/jvh.13775.
    PubMed     Abstract available


  220. KOFFAS A, Mak LY, Kennedy PTF
    Hepatitis delta virus: Disease assessment and stratification.
    J Viral Hepat. 2022 Dec 2. doi: 10.1111/jvh.13777.
    PubMed     Abstract available


  221. ABDELHAMED W, El-Kassas M
    Hepatocellular Carcinoma and Hepatitis C Virus Treatments: The Bold and The Beautiful.
    J Viral Hepat. 2022 Dec 2. doi: 10.1111/jvh.13778.
    PubMed     Abstract available


  222. FELD JJ, Forns X, Dylla DE, Kumada H, et al
    Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts.
    J Viral Hepat. 2022;29:1050-1061.
    PubMed     Abstract available


    November 2022
  223. HYDE Z, Roura R, Signer D, Patel A, et al
    Evaluation of a Pilot Emergency Department Linkage to Care Program for Patients Previously Diagnosed with Hepatitis C.
    J Viral Hepat. 2022 Nov 28. doi: 10.1111/jvh.13774.
    PubMed     Abstract available


  224. PERAZZO H, Silva MST, Coutinho C, Peixoto EM, et al
    Monkeypox outbreak as an opportunity to identify new cases of HCV infection in limited resource settings.
    J Viral Hepat. 2022 Nov 10. doi: 10.1111/jvh.13771.
    PubMed    


  225. LEE C, Emeto TI, Walsh N
    Prevalence of hepatitis B virus amongst refugees, asylum seekers and internally displaced persons in low- and middle-income countries: a systematic review.
    J Viral Hepat. 2022 Nov 10. doi: 10.1111/jvh.13770.
    PubMed     Abstract available


  226. LI G, Zhang P, Zhu Y
    Artificial liver support systems for hepatitis B virus-associated acute-on-chronic liver failure: A meta-analysis of the clinical literature.
    J Viral Hepat. 2022 Nov 3. doi: 10.1111/jvh.13767.
    PubMed     Abstract available


  227. GIRI S, Agrawal D, Afzalpurkar S, Gopan A, et al
    Tenofovir Versus Entecavir for Tertiary Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B Infection After Curative Therapy: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2022 Nov 2. doi: 10.1111/jvh.13766.
    PubMed     Abstract available


  228. HWANG SY, Yoo SH, Chang HY, Kim S, et al
    Baseline and on-treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals.
    J Viral Hepat. 2022 Nov 2. doi: 10.1111/jvh.13765.
    PubMed     Abstract available


    October 2022
  229. BITTENCOURT PL, Iasi MDSF, Viana MV, Crespo DM, et al
    Poor linkage to care may compromise the brazilian plan for hepatitis c elimination.
    J Viral Hepat. 2022 Oct 27. doi: 10.1111/jvh.13762.
    PubMed     Abstract available


  230. CASEY JL, Dore GJ, Grebely J, Matthews GV, et al
    Hepatitis C Virus-Specific Immune Responses Following Direct Acting Antivirals Administered During Recent Hepatitis C Virus Infection.
    J Viral Hepat. 2022 Oct 27. doi: 10.1111/jvh.13761.
    PubMed     Abstract available


  231. AGARWAL K, Xu J, Gane EJ, Nguyen TT, et al
    Safety, pharmacokinetics, and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: a randomized, placebo-controlled Phase 1 study.
    J Viral Hepat. 2022 Oct 27. doi: 10.1111/jvh.13764.
    PubMed     Abstract available


  232. CHADHA N, Turner A, Sterling RK
    Prevalence and predictors of abnormal alanine aminotransferase in patients with HCV who have achieved SVR.
    J Viral Hepat. 2022 Oct 27. doi: 10.1111/jvh.13763.
    PubMed     Abstract available


  233. SALPINI R, D'Anna S, Piermatteo L, Svicher V, et al
    Novel concepts on mechanisms underlying Hepatitis Delta virus persistence and related pathogenesis.
    J Viral Hepat. 2022 Oct 18. doi: 10.1111/jvh.13755.
    PubMed     Abstract available


  234. SQUIRES KE, Ogilvie L, Jucov A, Anastasiy I, et al
    A Randomized Phase 1b Trial of the Active Site Polymerase Inhibitor Nucleotide ATI-2173 in Patients With Chronic Hepatitis B Virus Infection.
    J Viral Hepat. 2022 Oct 6. doi: 10.1111/jvh.13753.
    PubMed     Abstract available


  235. HALL EW, Gounder P, Angles J, Nelson NP, et al
    Evaluating the Cost-Effectiveness of Hepatitis B Vaccination Strategies in High-impact Settings for Adults.
    J Viral Hepat. 2022 Oct 6. doi: 10.1111/jvh.13759.
    PubMed     Abstract available


  236. HEO M, Pericot-Valverde I, Niu J, Norton BL, et al
    More intensive hepatitis C virus care models promote adherence among people who inject drugs with active drug use: The PREVAIL Study.
    J Viral Hepat. 2022 Oct 5. doi: 10.1111/jvh.13756.
    PubMed     Abstract available


  237. MENDIZABAL M, Thompson M, Gonzalez-Ballerga E, Anders M, et al
    Implementation of a re-linkage to care strategy in patients with chronic hepatitis C who were lost to follow-up in Latin America.
    J Viral Hepat. 2022 Oct 5. doi: 10.1111/jvh.13758.
    PubMed     Abstract available


  238. BRYCE K, Smith C, Rodger A, Macdonald D, et al
    Falling treatment uptake in the hepatitis C care cascade is a growing threat to achieving elimination.
    J Viral Hepat. 2022 Oct 5. doi: 10.1111/jvh.13757.
    PubMed     Abstract available


    September 2022
  239. QIU LX, Huang Y, Quan JL, Bi ZF, et al
    The prognosis of hepatitis E infection in patients with chronic liver disease: a meta-analysis.
    J Viral Hepat. 2022 Sep 30. doi: 10.1111/jvh.13754.
    PubMed     Abstract available


  240. CAREY I, Christiana M, Marie-Ange M, Teresa B, et al
    Universal versus targeted screening for HCV infection in pregnancy in a diverse, multi-ethnic population: universal screening is more comprehensive.
    J Viral Hepat. 2022 Sep 22. doi: 10.1111/jvh.13752.
    PubMed     Abstract available


  241. CHOU C, Veracruz N, Chitnis AS, Wong RJ, et al
    Risk of Drug Induced Liver Injury in Chronic Hepatitis B and Tuberculosis Co-infection: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2022 Sep 22. doi: 10.1111/jvh.13751.
    PubMed     Abstract available


  242. MCDANIEL K, Utz AE, Akbashev MY, Fuller K, et al
    Safe co-administration of direct-acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: an international multicenter retrospective cohort study.
    J Viral Hepat. 2022 Sep 14. doi: 10.1111/jvh.13750.
    PubMed     Abstract available


  243. DONG C, Song Z, Sun C, Wang K, et al
    HBsAg Seroconversion in De Novo Hepatitis B Virus Infected Pediatric Liver Transplant Recipients with Antiviral Therapy.
    J Viral Hepat. 2022 Sep 12. doi: 10.1111/jvh.13749.
    PubMed     Abstract available


  244. QI T, Zhu C, Wang J, Li B, et al
    MELD Score <18 Rule out 28-day ACLF Development among Inpatients with Hepatitis B Related Previous Compensated Liver Disease.
    J Viral Hepat. 2022 Sep 8. doi: 10.1111/jvh.13747.
    PubMed     Abstract available


  245. YANG AH, Yardeni D, Hercun J, Kleiner DE, et al
    Shear Wave Elastography: How well does it perform in Chronic Hepatitis D Virus Infection?
    J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13745.
    PubMed     Abstract available


  246. HARTL L, Jachs M, Bauer D, Simbrunner B, et al
    An HCV hotline facilitates Hepatitis C elimination during the COVID-19 pandemic.
    J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13746.
    PubMed     Abstract available


  247. REYNOLDS L, Franco R, Prado M, Rodgers JB, et al
    Hepatitis C Active Viremia Over Time in an ED-based Testing Program: Impact, Disparities,.
    J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13744.
    PubMed     Abstract available


  248. JHA AK
    Hepatitis of unknown origin in children: Updated evidence and concise review.
    J Viral Hepat. 2022 Sep 5. doi: 10.1111/jvh.13743.
    PubMed     Abstract available


  249. LIEM KS, Chi H, Fung S, Wong DK, et al
    Early virologic relapse predicts ALT flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B.
    J Viral Hepat. 2022 Sep 1. doi: 10.1111/jvh.13742.
    PubMed     Abstract available


    August 2022
  250. SAMALA N, Wang RY, Auh S, Kara Balla A, et al
    Hepatitis E Prevalence and Infection in Solid-Organ Transplant Recipients in the United States.
    J Viral Hepat. 2022 Aug 29. doi: 10.1111/jvh.13739.
    PubMed     Abstract available


  251. YOUNOSSI ZM, Yu ML, El-Kassas M, Esmat G, et al
    Severe Impairment of Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Seen in Real-World Practices Across the World: Data from the Global Liver Registry.
    J Viral Hepat. 2022 Aug 29. doi: 10.1111/jvh.13741.
    PubMed     Abstract available


  252. YAMADA R, Morikawa K, Hotta K, Iwami D, et al
    Incidence of post-transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection.
    J Viral Hepat. 2022 Aug 29. doi: 10.1111/jvh.13740.
    PubMed     Abstract available


  253. MARTIN M, Roth PJ, Niu J, Pericot-Valverde I, et al
    Changes in Alcohol Use during Hepatitis C Treatment in Persons Who Inject Drugs.
    J Viral Hepat. 2022 Aug 23. doi: 10.1111/jvh.13737.
    PubMed     Abstract available


  254. BARRANCO MA, Rosenberg ES, Flanigan C, Shufelt S, et al
    A cross-sectional study of Hepatitis C prevalence and correlates among persons who inject drugs in rural and non-rural communities.
    J Viral Hepat. 2022 Aug 4. doi: 10.1111/jvh.13735.
    PubMed     Abstract available


  255. JIN D, Brener L, Treloar C
    Trust in healthcare providers among Chinese immigrants living with hepatitis B virus in Australia: A qualitative study.
    J Viral Hepat. 2022 Aug 3. doi: 10.1111/jvh.13736.
    PubMed     Abstract available


  256. XU L, Li X, Lu L, Liu X, et al
    HBV pgRNA profiles in Chinese HIV/HBV coinfected patients under pre- and posttreatment: a multicentre observational cohort study.
    J Viral Hepat. 2022;29:616-626.
    PubMed     Abstract available


    July 2022
  257. DENG X, Guo X, Gu H, Wang D, et al
    Anti-HBc-nonreactive occult hepatitis B infections with HBV genotypes B and C in vaccinated immunocompetent adults.
    J Viral Hepat. 2022 Jul 25. doi: 10.1111/jvh.13733.
    PubMed     Abstract available


  258. GAO N, Yu H, Zhang J, Mo Z, et al
    Role of Hepatitis B Surface Antibody in Seroreversion of Hepatitis B Surface Antigen in Patients Achieving Hepatitis B Surface Antigen Loss with Pegylated Interferon-Based Therapy.
    J Viral Hepat. 2022 Jul 24. doi: 10.1111/jvh.13734.
    PubMed     Abstract available


  259. MUTIMER D, Elsharkawy A, Hathorn E, Arunkumar S, et al
    Hepatitis B e antigen and e antibody in a multi-ethnic cohort of adult chronic hepatitis B virus patients followed at a single liver unit for a period of 20 years.
    J Viral Hepat. 2022 Jul 6. doi: 10.1111/jvh.13731.
    PubMed     Abstract available


  260. WANG H, Tong J, Xu X, Chen J, et al
    Reversibility of acute-on-chronic liver failure syndrome in hepatitis B virus-infected patients with and without prior decompensation.
    J Viral Hepat. 2022 Jul 6. doi: 10.1111/jvh.13732.
    PubMed     Abstract available


  261. KUMADA T, Toyoda H, Yasuda S, Ito T, et al
    Original article Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus.
    J Viral Hepat. 2022 Jul 5. doi: 10.1111/jvh.13728.
    PubMed     Abstract available


  262. PAPATHEODORIDI M, Papachristou E, Moschidis Z, Hadziyannis E, et al
    Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy.
    J Viral Hepat. 2022 Jul 5. doi: 10.1111/jvh.13729.
    PubMed     Abstract available


  263. FORD JS, Hollywood E, Steuble B, Meng Z, et al
    Risk Factors for Hepatitis C Virus Infection at a Large Urban Emergency Department.
    J Viral Hepat. 2022 Jul 5. doi: 10.1111/jvh.13730.
    PubMed     Abstract available


    June 2022
  264. FACTOR SH, Fierer DS
    Can Treatment, Without Prevention, Eliminate Hepatitis C Among Men Who Have Sex With Men?
    J Viral Hepat. 2022 Jun 24. doi: 10.1111/jvh.13726.
    PubMed    


  265. SHATA MTM, Hetta HF, Sharma Y, Sherman KE, et al
    Viral Hepatitis in Pregnancy.
    J Viral Hepat. 2022 Jun 24. doi: 10.1111/jvh.13725.
    PubMed     Abstract available


  266. TAYE BW, Valery PC, Clark PJ
    Targeted antiviral treatment of hepatitis B virus in culturally and linguistically diverse populations to achieve elimination targets in Australia.
    J Viral Hepat. 2022 Jun 24. doi: 10.1111/jvh.13727.
    PubMed     Abstract available


  267. XU JH, Fan YN, Yu YY, Si CW, et al
    240-week Entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C.
    J Viral Hepat. 2022 Jun 23. doi: 10.1111/jvh.13724.
    PubMed     Abstract available


  268. TRAEGER MW, van Santen DK, Sacks-Davis R, Asselin J, et al
    Impact of COVID-19 lockdown restrictions on hepatitis C testing in Australian primary care services providing care for people who inject drugs.
    J Viral Hepat. 2022 Jun 20. doi: 10.1111/jvh.13723.
    PubMed     Abstract available


  269. YAO N, Wang J, Wu Y, Zhu Y, et al
    Frequent alanine aminotransferase flares and promising antiviral therapy efficacy during the preschool age: an opportunity to achieve HBsAg loss in children with mother-to-child transmitted hepatitis B.
    J Viral Hepat. 2022 Jun 20. doi: 10.1111/jvh.13720.
    PubMed     Abstract available


  270. LIM J, Lee JB, An J, Song GW, et al
    Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000-Korean outcome study.
    J Viral Hepat. 2022 Jun 19. doi: 10.1111/jvh.13721.
    PubMed     Abstract available


  271. CHU JH, Huang Y, Xie DY, Deng H, et al
    Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patients.
    J Viral Hepat. 2022 Jun 19. doi: 10.1111/jvh.13722.
    PubMed     Abstract available


  272. RIOS-HINCAPIE CY, Murad-Rivera R, Tohme RA, Ropero AM, et al
    Progress towards the elimination of hepatitis B in children in Colombia: a novel two-phase study approach.
    J Viral Hepat. 2022 Jun 16. doi: 10.1111/jvh.13719.
    PubMed     Abstract available


  273. SHIHA G, Soliman R, Mikhail NNH, Carrat F, et al
    International Multicenter Validation of GES score for HCC risk stratification in chronic hepatitis C patients.
    J Viral Hepat. 2022 Jun 3. doi: 10.1111/jvh.13717.
    PubMed     Abstract available


  274. EVON DM, Dong M, Reeve BB, Peter J, et al
    Sustainable and Equivalent Improvements in Symptoms and Functional Well-Being Following Viral Cure from Ledipasvir/Sofosbuvir versus Elbasvir/Grazoprevir for Chronic Hepatitis C Infection: Findings from the randomized PRIORITIZE trial.
    J Viral Hepat. 2022 Jun 3. doi: 10.1111/jvh.13716.
    PubMed     Abstract available


  275. HSU WF, Lai HC, Chuang PH, Su WP, et al
    Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver-related complications in patients with chronic hepatitis C receiving direct-acting antiviral agents.
    J Viral Hepat. 2022 Jun 3. doi: 10.1111/jvh.13715.
    PubMed     Abstract available


  276. ROBINS A, Dolman G, Williams S, Gelson W, et al
    Hepatitis E Case Series. A UK Experience.
    J Viral Hepat. 2022 Jun 2. doi: 10.1111/jvh.13714.
    PubMed     Abstract available


    May 2022
  277. MARKAKIS GE, Papatheodoridis GV, Cholongitas E
    Epidemiology and treatment of hepatitis E in the liver transplantation setting: A literature review.
    J Viral Hepat. 2022 May 29. doi: 10.1111/jvh.13709.
    PubMed     Abstract available


  278. ASKAR S, Jelley R, McQue K, Allsop C, et al
    Determining the frequency and characteristics of Hepatitis C reinfections in North East England.
    J Viral Hepat. 2022 May 29. doi: 10.1111/jvh.13707.
    PubMed     Abstract available


  279. RAMOS-RINCON JM, Pinargote-Celorio H, de Mendoza C, Ramos-Belinchon C, et al
    Hepatitis C Hospitalizations in Spain and Impact of New Curative Antiviral Therapies.
    J Viral Hepat. 2022 May 29. doi: 10.1111/jvh.13708.
    PubMed     Abstract available


  280. BOLLERUP S, Hallager S, Engsig F, Mocroft A, et al
    Mortality and cause of death in persons with chronic hepatitis B virus infection versus healthy persons from the general population in Denmark.
    J Viral Hepat. 2022 May 27. doi: 10.1111/jvh.13713.
    PubMed     Abstract available


  281. CHEN L, Zhu L, Lu X, Ming X, et al
    TRPM2 regulates autophagy to participate in hepatitis B virus replication.
    J Viral Hepat. 2022 May 27. doi: 10.1111/jvh.13710.
    PubMed     Abstract available


  282. EYMIEUX S, Hourioux C, Marlet J, Moreau A, et al
    A morphometric analysis of hepatitis B subviral particles shows no correlation of filament proportion and length with clinical stage and genotype.
    J Viral Hepat. 2022 May 27. doi: 10.1111/jvh.13712.
    PubMed     Abstract available


  283. MARLEY G, Seto WK, Yan W, Chan P, et al
    What facilitates hepatitis B and hepatitis C testing and the role of stigma among primary care patients in China?
    J Viral Hepat. 2022 May 27. doi: 10.1111/jvh.13711.
    PubMed     Abstract available


  284. PRINSENBERG T, Schinkel J, Zantkuijl P, Davidovich U, et al
    Internet-guided HCV-RNA testing: A promising tool to achieve hepatitis C micro-elimination among men who have sex with men.
    J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13706.
    PubMed     Abstract available


  285. CARSON JM, Hajarizadeh B, Hanson J, O'Beirne J, et al
    Retreatment for hepatitis C virus direct acting antiviral therapy virological failure in primary and tertiary settings: the REACH-C cohort.
    J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13705.
    PubMed     Abstract available


  286. ZHENG K, Xia T, Liu N, Xia X, et al
    MicroRNA-206 inhibits HCV proliferation through depressing ACC1 lipid synthesis signaling pathway.
    J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13703.
    PubMed     Abstract available


  287. MASLAC O, Wagner J, Sozzi V, Mason H, et al
    Secreted Hepatitis B virus splice variants differ by HBV genotype and across phases of chronic hepatitis B infection.
    J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13702.
    PubMed     Abstract available


  288. BEER L, Inglis S, Malaguti A, Byrne C, et al
    Randomised Clinical Trial: Direct-acting antivirals as treatment for hepatitis C in people who inject drugs: delivered in needle and syringe programs via directly observed therapy versus fortnightly collection.
    J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13701.
    PubMed     Abstract available


  289. ZHOU G, Chen C, Han G, Jiang H, et al
    Relationship between different hepatitis B virus infection status and gestational diabetes mellitus prevalence among pregnant women with chronic HBV infection: a retrospective study.
    J Viral Hepat. 2022 May 18. doi: 10.1111/jvh.13700.
    PubMed     Abstract available


  290. XU Y, Qi W, Wang X, Zhang Y, et al
    Signal transducer and activator of transcription 3 cooperates with androgen receptor/cell cycle-related kinase signalling pathway in the progression of hepatitis B virus infection and gender differences.
    J Viral Hepat. 2022 May 14. doi: 10.1111/jvh.13699.
    PubMed     Abstract available


  291. VARGAS-ACCARINO E, Martinez-Camprecios J, Dominguez-Hernandez R, Rando-Segura A, et al
    Cost-effectiveness analysis of an active search to retrieve HCV patients lost to follow-up (RELINK-C strategy) and the impact of COVID-19.
    J Viral Hepat. 2022 May 12. doi: 10.1111/jvh.13686.
    PubMed     Abstract available


  292. MASHIBA T, Joko K, Kurosaki M, Ochi H, et al
    Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Live
    J Viral Hepat. 2022 May 12. doi: 10.1111/jvh.13684.
    PubMed     Abstract available


  293. JONES AT, Briones C, Tran T, Moreno-Walton L, et al
    Closing the hepatitis C treatment gap: United States strategies to improve retention in care.
    J Viral Hepat. 2022 May 12. doi: 10.1111/jvh.13685.
    PubMed     Abstract available


  294. HEALY K, Freij U, Ellerstad M, Aulin LBS, et al
    Evaluating the prevalence of Hepatitis E virus infection in a large cohort of European blood donors, 2015-2018.
    J Viral Hepat. 2022 May 2. doi: 10.1111/jvh.13682.
    PubMed     Abstract available


  295. KUWANO A, Yada M, Nagasawa S, Tanaka K, et al
    Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib.
    J Viral Hepat. 2022 May 2. doi: 10.1111/jvh.13681.
    PubMed     Abstract available


    March 2022
  296. LEE J, Ahn SB, Yim SY, An J, et al
    Efficacy and Safety of Direct-Acting Antiviral Therapy for Hepatitis C Virus in Elderly Patients (>/= 65 years old): A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13679.
    PubMed     Abstract available


  297. TERGAST TL, Blach S, Tacke F, Berg T, et al
    Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13680.
    PubMed     Abstract available


  298. HASSAN A, Agustin HGS, Burke L, Kofron R, et al
    Low Incidence and Prevalence of Hepatitis C in Two Cohorts of HIV Pre-Exposure Prophylaxis Adherence Interventions in Men Who Have Sex with Men in Southern California.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13678.
    PubMed     Abstract available


  299. WARD E, Carlisle N, Williams E, Heath SL, et al
    Prevalence of Hepatitis C in Sexual Assault Survivors Presenting to a SANE Clinic: A Descriptive Analysis.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13675.
    PubMed     Abstract available


  300. LIU R, Li M, Lu Y, Zhang L, et al
    Hepatitis B core-related antigen serum levels are associated with significant liver fibrosis in treatment-naive chronic HBV infection patients.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13674.
    PubMed     Abstract available


  301. NEBBIA G, Ruf M, Hunter L, Balasegaram S, et al
    The VirA+EmiC project - Evaluating real-world effectiveness and sustainability of integrated routine opportunistic hepatitis B and C testing in a large urban emergency department.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13676.
    PubMed     Abstract available


  302. KRARUP HB, Rex KF, Andersen S
    Mortality in Greenlanders with chronic hepatitis B virus infection.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13673.
    PubMed     Abstract available


  303. OZGA JE, Syvertsen JL, Pollini RA
    Hepatitis C Antibody Prevalence, Correlates, and Barriers to Care among People Who Inject Drugs in Central California.
    J Viral Hepat. 2022 Mar 31. doi: 10.1111/jvh.13677.
    PubMed     Abstract available


  304. KRINGS A, Schmidt D, Meixenberger K, Bannert N, et al
    Decreasing prevalence and stagnating incidence of Hepatitis C-coinfection among a cohort of HIV-1-positive patients, with a majority of men who have sex with men, in Germany, 1996-2019.
    J Viral Hepat. 2022 Mar 18. doi: 10.1111/jvh.13670.
    PubMed     Abstract available


  305. MA Z, Qin Y, Jia Y, Yiran X, et al
    Thyroid dysfunction incidence and risk factors in Chinese chronic hepatitis B patients treated with pegylated interferon alpha: a long-term follow-up study.
    J Viral Hepat. 2022 Mar 16. doi: 10.1111/jvh.13667.
    PubMed     Abstract available


  306. MORGAN JR, Marsh E, Savinkina A, Shilton S, et al
    Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral based treatment regimens: evidence from a global dataset.
    J Viral Hepat. 2022 Mar 12. doi: 10.1111/jvh.13672.
    PubMed     Abstract available


  307. VERACRUZ N, Gish RG, Cheung R, Chitnis AS, et al
    Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019.
    J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13663.
    PubMed     Abstract available


  308. HOWELL J, Traeger MW, Williams B, Layton C, et al
    The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study.
    J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13664.
    PubMed     Abstract available


  309. CHROMY D, Bauer DJM, Simbrunner B, Jachs M, et al
    'Viennese epidemic' of acute HCV in the era of direct-acting antivirals.
    J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13665.
    PubMed     Abstract available


  310. EL EKIABY M, Tanaka J, van Drimmelen H, Allain JP, et al
    Infectivity of hepatitis B virus (HBV) surface antigen (HBsAg) positive plasma with undetectable HBV-DNA: Can HBsAg screening be discontinued in Egyptian blood donors?
    J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13666.
    PubMed     Abstract available


  311. AKIYAMA MJ, Riback L, Nyakowa M, Musyoki H, et al
    Hepatitis C Treatment Outcomes Among People Who Inject Drugs Accessing Harm Reduction Settings in Kenya.
    J Viral Hepat. 2022 Mar 11. doi: 10.1111/jvh.13662.
    PubMed     Abstract available


  312. ZENG X, Ayibaota B, Tuerhanbayi B, Zheng M, et al
    The altered HLA-DQ expression in peripheral blood T cells of chronic hepatitis B patients characterizes the function of T cells.
    J Viral Hepat. 2022 Mar 10. doi: 10.1111/jvh.13669.
    PubMed     Abstract available


  313. WANG Y, Liao H, Deng Z, Liu Y, et al
    Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues.
    J Viral Hepat. 2022 Mar 10. doi: 10.1111/jvh.13671.
    PubMed     Abstract available


  314. KAUR H, Dhiman RK, Kulkarni AV, Premkumar M, et al
    Improvement of Chronic HCV infection related Depression, Anxiety, and Neurocognitive performance in persons achieving SVR-12: a Real-world Cohort Study.
    J Viral Hepat. 2022 Mar 10. doi: 10.1111/jvh.13668.
    PubMed     Abstract available


  315. NEPHEW LD, Wang Y, Mohamed K, Nichols D, et al
    Removal of Medicaid Restrictions were Associated with Increased Hepatitis-C Virus Treatment Rates, But Disparities Persist.
    J Viral Hepat. 2022 Mar 7. doi: 10.1111/jvh.13661.
    PubMed     Abstract available


  316. JI DZ, Pang XY, Shen DT, Liu SN, et al
    Global prevalence of occult Hepatitis B: a systematic review and meta-analysis.
    J Viral Hepat. 2022 Mar 7. doi: 10.1111/jvh.13660.
    PubMed     Abstract available


  317. TAN Q, Chen J, Gao G, Yizhang, et al
    Adenovirus vector encoding TPPII ignites HBV-specific CTL response by activating autophagy in CD8+ T cell.
    J Viral Hepat. 2022;29:178-188.
    PubMed     Abstract available


    February 2022
  318. HOSSEINI-HOOSHYAR S, Alavi M, Martinello M, Valerio H, et al
    Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study.
    J Viral Hepat. 2022 Feb 17. doi: 10.1111/jvh.13658.
    PubMed     Abstract available


  319. WU G, Zhou A, Kwon S
    Integrating Hepatitis C Virus Screening of Baby Boomers at a Community Hospital Emergency Department.
    J Viral Hepat. 2022 Feb 13. doi: 10.1111/jvh.13654.
    PubMed     Abstract available


  320. CHON YE, Park SY, Kim SU, Hong HP, et al
    Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study.
    J Viral Hepat. 2022 Feb 13. doi: 10.1111/jvh.13656.
    PubMed     Abstract available


  321. FENG R, Liu Y, Zhu XL, Zhai WY, et al
    Recombinant human thrombopoietin increases platelet count in severe thrombocytopenic patients with hepatitis B related cirrhosis: multi-center real-world observational study.
    J Viral Hepat. 2022 Feb 13. doi: 10.1111/jvh.13655.
    PubMed     Abstract available


  322. YARDENI D, Heller T, Koh C
    Chronic hepatitis D - What is changing?
    J Viral Hepat. 2022 Feb 4. doi: 10.1111/jvh.13651.
    PubMed     Abstract available


  323. WU A, Liu Y
    Use of HBV DNA and liver stiffness in predicting clinical events in patients with chronic hepatitis B.
    J Viral Hepat. 2022 Feb 4. doi: 10.1111/jvh.13653.
    PubMed    


  324. KHERA T, Madsen LW, Du Y, Lillevang ST, et al
    Soluble inflammatory mediators identify HCV patients who may be cured with four weeks of antiviral treatment.
    J Viral Hepat. 2022 Feb 4. doi: 10.1111/jvh.13652.
    PubMed     Abstract available


    January 2022
  325. HUA R, Kong F, Wen X, Xiong Q, et al
    Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection - an open-label, phase 2 study.
    J Viral Hepat. 2022 Jan 26. doi: 10.1111/jvh.13650.
    PubMed     Abstract available


  326. WU S, Yuan H, Fan H, Xu Y, et al
    Evolutionary characteristics and immune mutation of hepatitis C virus genotype 1b among intravenous drug users in mainland, China.
    J Viral Hepat. 2022 Jan 25. doi: 10.1111/jvh.13647.
    PubMed     Abstract available


  327. LU Z, Zhou Y, Yan R, Deng X, et al
    Post vaccination serologic testing of infants born to hepatitis B surface antigen positive mothers is more Cost-effective in Zhejiang Province,China: A Markov chain analysis.
    J Viral Hepat. 2022 Jan 25. doi: 10.1111/jvh.13649.
    PubMed     Abstract available


  328. CHOI WM, Lim YS
    Use of HBV DNA and liver stiffness in predicting clinical events in patients with chronic hepatitis B.
    J Viral Hepat. 2022 Jan 25. doi: 10.1111/jvh.13648.
    PubMed    


  329. STOCKDALE AJ, Kreuels B, Shawa IT, Meiring JE, et al
    A clinical and molecular epidemiological survey of hepatitis C in Blantyre, Malawi suggests an historic mechanism of transmission.
    J Viral Hepat. 2022 Jan 25. doi: 10.1111/jvh.13646.
    PubMed     Abstract available


  330. WASUWANICH P, Striley CW, Kamili S, Teshale EH, et al
    Hepatitis D-Associated Hospitalizations in the United States: 2010-2018.
    J Viral Hepat. 2022 Jan 25. doi: 10.1111/jvh.13645.
    PubMed     Abstract available


  331. ZHANG Y, Yang M, Huang X, Yang H, et al
    Comments on: The role of caesarean section and nonbreastfeeding in preventing mother-to-child transmission of hepatitis B virus in HBsAg-and HBeAg-positive mothers: results from a prospective cohort study and a meta-analysis.
    J Viral Hepat. 2022 Jan 8. doi: 10.1111/jvh.13641.
    PubMed    


  332. PAN YC, Jia ZF, Wu YH, Lv HY, et al
    Response to comments on: The role of caesarean section and nonbreastfeeding in preventing mother-to-child transmission of hepatitis B virus in HBsAg-and HBeAg-positive mothers: results from a prospective cohort study and a meta-analysis.
    J Viral Hepat. 2022 Jan 6. doi: 10.1111/jvh.13642.
    PubMed    


  333. IKENAGA H, Uchida-Kobayashi S, Tamori A, Odagiri N, et al
    Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment.
    J Viral Hepat. 2022;29:52-59.
    PubMed     Abstract available


  334. ELZEFZAFY W, Soliman R, Saleh L, Mahmoud S, et al
    Seroprevalence and epidemiological characteristics of HDV infection among HBV patients in the Nile Delta, Egypt.
    J Viral Hepat. 2022;29:87-90.
    PubMed     Abstract available


    December 2021
  335. ZHOU Y, Li J, Gordon SC, Trudeau S, et al
    Laboratory monitoring and antiviral treatment for chronic hepatitis B among routine care patients in the United States.
    J Viral Hepat. 2021 Dec 14. doi: 10.1111/jvh.13639.
    PubMed     Abstract available


  336. WANG XD, Pan CW, Zhou GY, Gao F, et al
    Effect of liver steatosis on liver stiffness measurement in chronic hepatitis B patients with normal serum alanine aminotransferase levels: A multicentre cohort study.
    J Viral Hepat. 2021 Dec 13. doi: 10.1111/jvh.13640.
    PubMed     Abstract available


  337. CHOI HSJ, Sonneveld MJ, Farag MS, Brouwer WP, et al
    Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection.
    J Viral Hepat. 2021;28:1729-1737.
    PubMed     Abstract available


  338. DJORDJEVIC F, Ryan K, Gunn J, Brener L, et al
    Health service utilization and experiences of stigma amongst people who inject drugs in Melbourne, Australia.
    J Viral Hepat. 2021;28:1738-1743.
    PubMed     Abstract available


    November 2021
  339. MANDEL E, Peci A, Cronin K, Capraru CI, et al
    The Impact of the First, Second, and Third Waves of COVID-19 on Hepatitis B and C Testing in Ontario, Canada.
    J Viral Hepat. 2021 Nov 25. doi: 10.1111/jvh.13637.
    PubMed     Abstract available


  340. GIADANS CG, Rios DA, Ameigeiras B, Haddad L, et al
    Intrahepatic immune infiltrate in chronic hepatitis B and chronic hepatitis C: Similar but not the same.
    J Viral Hepat. 2021 Nov 25. doi: 10.1111/jvh.13635.
    PubMed     Abstract available


  341. LEMOINE M, Ndow G, Shimakawa Y
    Improving disease knowledge is critical to eliminate hepatitis B.
    J Viral Hepat. 2021 Nov 22. doi: 10.1111/jvh.13633.
    PubMed     Abstract available


  342. FORNS X, Colom J, Garcia-Retortillo M, Quer JC, et al
    Point-of-care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination.
    J Viral Hepat. 2021 Nov 22. doi: 10.1111/jvh.13634.
    PubMed     Abstract available


  343. MOHAMED EI, El-Ghnam SM, Bayoumi AM, Abdel-Mageed SM, et al
    Electronic Nose versus Quadrupole Mass Spectrometry for Identifying Viral Hepatitis C Patients.
    J Viral Hepat. 2021 Nov 12. doi: 10.1111/jvh.13630.
    PubMed     Abstract available


  344. CHIDWICK K, Myton R, Rodgers A, Jun M, et al
    A cluster randomized controlled trial of a MedicineInsight Educational Quality Improvement Programme to improve the diagnosis and treatment of chronic hepatitis C in general practice (the EQUIP-HEPC trial).
    J Viral Hepat. 2021 Nov 11. doi: 10.1111/jvh.13629.
    PubMed     Abstract available


  345. JO AJ, Choi WM, Kim HJ, Choi SH, et al
    A risk scoring system to predict clinical events in chronic hepatitis B virus infection: A nationwide cohort study.
    J Viral Hepat. 2021 Nov 11. doi: 10.1111/jvh.13631.
    PubMed     Abstract available


  346. CHANG HL, Wen WH, Lee CN, Chiu YE, et al
    Kinetics of Hepatitis B Surface Antigen in Pregnant Women with and without Tenofovir Disoproxil Fumarate.
    J Viral Hepat. 2021 Nov 1. doi: 10.1111/jvh.13628.
    PubMed     Abstract available


  347. GANE E, de Ledinghen V, Dylla DE, Rizzardini G, et al
    Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.
    J Viral Hepat. 2021;28:1635-1642.
    PubMed     Abstract available


    October 2021
  348. JUGNARAIN DV, Halford R, Smith S, Hickman M, et al
    Role of peer support in a hepatitis C elimination program.
    J Viral Hepat. 2021 Oct 18. doi: 10.1111/jvh.13626.
    PubMed     Abstract available


  349. KUWANO A, Yada M, Nagasawa S, Tanaka K, et al
    Serum alpha-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
    J Viral Hepat. 2021 Oct 18. doi: 10.1111/jvh.13625.
    PubMed     Abstract available


  350. RAMIREZ MENA A, Tine JM, Fortes L, Ndiaye O, et al
    Hepatitis B screening practices and viral control among persons living with HIV in urban Senegal.
    J Viral Hepat. 2021 Oct 5. doi: 10.1111/jvh.13615.
    PubMed     Abstract available


  351. ZHOU Y, Lu Z, He H, Yan R, et al
    Influencing factors and necessity of post-vaccination serologic testing follow-up for HBsAg-positive mothers and their infants: A 5-year prospective study in Zhejiang Province, China (2016-2020).
    J Viral Hepat. 2021;28:1413-1421.
    PubMed     Abstract available


    September 2021
  352. NISHIGUCHI J, McNamara A, Surlyn CS, Eagen KV, et al
    Efficacy of an eConsult Service to Cure Hepatitis C in Primary Care.
    J Viral Hepat. 2021 Sep 29. doi: 10.1111/jvh.13616.
    PubMed     Abstract available


  353. COPPOLA C, Masarone M, Bartoli M, Staiano L, et al
    Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: a cohort study.
    J Viral Hepat. 2021 Sep 29. doi: 10.1111/jvh.13623.
    PubMed     Abstract available


  354. STROFFOLINI T, Morisco F, Ferrigno L, Pontillo G, et al
    Acute Delta Hepatitis in Italy spanning three decades (1991-2019): evidence for the effectiveness of the hepatitis B vaccination campaign.
    J Viral Hepat. 2021 Sep 29. doi: 10.1111/jvh.13620.
    PubMed     Abstract available


  355. HARNEY BL, Brereton R, Whitton B, Pietrzak D, et al
    Letter in response: Psychiatrists can treat hepatitis C.
    J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13619.
    PubMed     Abstract available


  356. RODER C, Nguyen P, Harvey C, Wardrop M, et al
    Psychiatrists can treat hepatitis C.
    J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13622.
    PubMed     Abstract available


  357. ROSATO V, Ascione A, Nevola R, Fracanzani AL, et al
    Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: a multicenter prospective study.
    J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13617.
    PubMed     Abstract available


  358. SOHN W, Chang Y, Cho YK, Hong YS, et al
    Liver fibrosis scores and risk of liver-related mortality in young adults with chronic hepatitis B: A cohort study.
    J Viral Hepat. 2021 Sep 28. doi: 10.1111/jvh.13618.
    PubMed     Abstract available


  359. CAVEN M, Baiano CX, Robinson EM, Stephens B, et al
    Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland.
    J Viral Hepat. 2021 Sep 15. doi: 10.1111/jvh.13614.
    PubMed     Abstract available


  360. KOUTSIANAS C, Hadziyannis E, Thomas K, Deutsch M, et al
    Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents.
    J Viral Hepat. 2021 Sep 8. doi: 10.1111/jvh.13610.
    PubMed     Abstract available


  361. MARCELLIN F, Di Beo V, Esterle L, Abgrall S, et al
    Post-HCV cure self-reported changes in physical activity, eating behaviors, and fatigue in people living with HIV (ANRS CO13 HEPAVIH).
    J Viral Hepat. 2021 Sep 2. doi: 10.1111/jvh.13605.
    PubMed     Abstract available


  362. DOUMBIA M, Sevede D, Kouakou V, Kouakou C, et al
    Viral and bacterial factors of mother-to-child transmission of hepatitis B virus.
    J Viral Hepat. 2021 Sep 1. doi: 10.1111/jvh.13607.
    PubMed     Abstract available


  363. HAMDIUI N, van Steenbergen J, Rocha LEC, Meiberg A, et al
    Hepatitis B screening among immigrants: how to successfully reach the Moroccan community.
    J Viral Hepat. 2021 Sep 1. doi: 10.1111/jvh.13604.
    PubMed     Abstract available


  364. CHEUNG KW, Seto MTY, Tsui PM, So PL, et al
    Knowledge, perception and expectation of management of hepatitis B infection among pregnant hepatitis B carriers in Hong Kong.
    J Viral Hepat. 2021 Sep 1. doi: 10.1111/jvh.13609.
    PubMed     Abstract available


  365. ERKEN R, Andre P, Roy E, Kootstra N, et al
    Farnesoid X receptor agonist for the treatment of chronic hepatitis B; a safety study.
    J Viral Hepat. 2021 Sep 1. doi: 10.1111/jvh.13608.
    PubMed     Abstract available


  366. GARCIA-CEHIC D, Rando A, Rodriguez-Frias F, Gregori J, et al
    Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.
    J Viral Hepat. 2021;28:1319-1324.
    PubMed     Abstract available


    August 2021
  367. TSAI HJ, Chuang YW, Yang SS, Chang YZ, et al
    Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease.
    J Viral Hepat. 2021 Aug 31. doi: 10.1111/jvh.13603.
    PubMed     Abstract available


  368. WANG L, Zhao J, Liu J, Zhen C, et al
    Long-term benefits of interferon-alpha therapy in children with HBeAg-positive immune-active chronic hepatitis B.
    J Viral Hepat. 2021 Aug 26. doi: 10.1111/jvh.13598.
    PubMed     Abstract available


  369. LEE HW, Cho YY, Lee H, Lee JS, et al
    Effect of tenofovir alafenamide versus tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B.
    J Viral Hepat. 2021 Aug 26. doi: 10.1111/jvh.13601.
    PubMed     Abstract available


  370. CHEN Y, Zhao YL, Hao ZY, Zhang XJ, et al
    Long-term persistence of anti-HAV antibody conferred by a single dose of live-attenuated hepatitis A vaccine: results from 17-year follow-up.
    J Viral Hepat. 2021 Aug 26. doi: 10.1111/jvh.13602.
    PubMed     Abstract available


  371. WONG RJ, Cheung R, Gish RG, Chitnis AS, et al
    Prevalence of Hepatitis E Infection among Adults with Concurrent Chronic Liver Disease.
    J Viral Hepat. 2021 Aug 20. doi: 10.1111/jvh.13597.
    PubMed     Abstract available


  372. CHEN B, Huang H, Pan CQ
    The Role of Gut Microbiota in Hepatitis B Disease Progression and Treatment.
    J Viral Hepat. 2021 Aug 20. doi: 10.1111/jvh.13595.
    PubMed     Abstract available


  373. PALMER AY, Chan K, Gold J, Layton C, et al
    A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.
    J Viral Hepat. 2021 Aug 20. doi: 10.1111/jvh.13596.
    PubMed     Abstract available


  374. CHANG JW, Lee JS, Lee HW, Kim BK, et al
    No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B.
    J Viral Hepat. 2021 Aug 12. doi: 10.1111/jvh.13594.
    PubMed     Abstract available


  375. BALL LE, Agana B, Comte-Walters S, Rockey DC, et al
    Hepatitis C Virus Treatment with Direct Acting Antivirals Induces Rapid Changes in the Hepatic Proteome.
    J Viral Hepat. 2021 Aug 11. doi: 10.1111/jvh.13593.
    PubMed     Abstract available


  376. FREELAND C, Racho R, Kamischke M, Moraras K, et al
    Cure everyone and vaccinate the rest: The patient perspective on future hepatitis B treatment.
    J Viral Hepat. 2021 Aug 7. doi: 10.1111/jvh.13592.
    PubMed     Abstract available


  377. LEE WM, King WC, Janssen HLA, Ghany MG, et al
    Hepatitis B e Antigen Loss in Adults and Children with Chronic Hepatitis B Living in North America: A Prospective Cohort Study.
    J Viral Hepat. 2021 Aug 6. doi: 10.1111/jvh.13591.
    PubMed     Abstract available


  378. PERIERES L, Protopopescu C, Lo G, Marcellin F, et al
    Sibling status, home birth, tattoos and stitches are risk factors for chronic hepatitis B virus infection in Senegalese children: a cross-sectional survey.
    J Viral Hepat. 2021 Aug 6. doi: 10.1111/jvh.13589.
    PubMed     Abstract available


  379. DJEBALI-TRABELSI A, Marot A, Andre C, Deltenre P, et al
    Large-scale screening is not useful for identifying individuals with hepatitis B or C virus infection: a prospective Swiss study.
    J Viral Hepat. 2021 Aug 3. doi: 10.1111/jvh.13588.
    PubMed     Abstract available


  380. XU C, Bao Y, Zuo J, Li Y, et al
    Maternal chronic hepatitis B virus infection and the risk of preterm birth: a retrospective cohort analysis in Chinese Women.
    J Viral Hepat. 2021 Aug 3. doi: 10.1111/jvh.13585.
    PubMed     Abstract available


  381. KNOP V, Hoppe D, Vermehren J, Troetschler S, et al
    Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 year follow-up of a prospective longitudinal study.
    J Viral Hepat. 2021 Aug 3. doi: 10.1111/jvh.13587.
    PubMed     Abstract available


  382. HUPPE D, Stoehr A, Buggisch P, Mauss S, et al
    The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R).
    J Viral Hepat. 2021 Aug 2. doi: 10.1111/jvh.13586.
    PubMed     Abstract available


    July 2021
  383. SANTOS-LIMA C, Souza-Marques B, Vieira F, Schinoni MI, et al
    Neuropsychological effects of direct-acting antiviral treatment for HCV subjects: a systematic review.
    J Viral Hepat. 2021 Jul 28. doi: 10.1111/jvh.13584.
    PubMed     Abstract available


  384. WANG Y, Zhao Z, Zhang H, Lin Q, et al
    Estimating the transmissibility of hepatitis C: a modelling study in Yichang City, China.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13582.
    PubMed     Abstract available


  385. DEL ROSARIO A, Eldredge JD, Doorley S, Mishra SI, et al
    Hepatitis C Virus Care Cascade in Persons Experiencing Homelessness in the United States in the Era of Direct-Acting Antiviral Agents: A Scoping Review.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13583.
    PubMed     Abstract available


  386. OHKI T, Satov K, Kondo M, Goto E, et al
    Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13579.
    PubMed     Abstract available


  387. ZHANG S, Chen Z, Wei J, Chi X, et al
    A model based on clinico-biochemical characteristics and deep learning features from MR images for assessing necroinflammatory activity in chronic hepatitis B.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13578.
    PubMed     Abstract available


  388. YOUSAFZAI MT, Bajis S, Alavi M, Grebely J, et al
    Treatment cascade of care for chronic hepatitis C virus infection globally: Systematic review and meta-analysis.
    J Viral Hepat. 2021 Jul 26. doi: 10.1111/jvh.13574.
    PubMed     Abstract available


  389. HEYWOOD A, Dyda A, Hu W, Saha A, et al
    Seroprevalence of hepatitis B antibodies among international and domestic university students.
    J Viral Hepat. 2021 Jul 26. doi: 10.1111/jvh.13580.
    PubMed     Abstract available


  390. KAMAL H, Fornes R, Simin J, Stal P, et al
    Risk of Hepatocellular Carcinoma in Hepatitis B and D Virus Co-Infected Patients: A Systematic Review and Meta-analysis of Longitudinal studies.
    J Viral Hepat. 2021 Jul 22. doi: 10.1111/jvh.13577.
    PubMed     Abstract available


  391. BISCHOFF J, Mauss S, Lutz T, Cordes C, et al
    Late presentation of chronic hepatitis C patients in the era of direct acting antivirals - Data from the German Hepatitis C-Registry.
    J Viral Hepat. 2021 Jul 21. doi: 10.1111/jvh.13576.
    PubMed     Abstract available


  392. BARDSLEY M, Heinsbroek E, Harris R, Croxford S, et al
    The Impact Of Direct-Acting Antivirals On Hepatitis C Viraemia Among People Who Inject Drugs In England; Real-World Data 2011-2018.
    J Viral Hepat. 2021 Jul 16. doi: 10.1111/jvh.13575.
    PubMed     Abstract available


  393. NA JE, Sinn DH, Lee JH, Jang HJ, et al
    Efficacy of entecavir vs tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response.
    J Viral Hepat. 2021 Jul 12. doi: 10.1111/jvh.13572.
    PubMed     Abstract available


  394. VARCHETTA S, Mele D, D'Ambrosio R, Perbellini R, et al
    A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C.
    J Viral Hepat. 2021 Jul 6. doi: 10.1111/jvh.13570.
    PubMed     Abstract available


  395. LI J, Qu L, Sun X, Liu Y, et al
    Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg positive chronic hepatitis B naive patients.
    J Viral Hepat. 2021 Jul 6. doi: 10.1111/jvh.13571.
    PubMed     Abstract available


  396. ERICE A, Varillas-Delgado D, Caballero C
    Prevalence and characteristics of hepatitis C virus infection detected by extended screening of working-age adults in Madrid (Spain).
    J Viral Hepat. 2021 Jul 5. doi: 10.1111/jvh.13564.
    PubMed     Abstract available


  397. KAMALAPIRAT T, Ungtrakul T
    Reply to "Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B".
    J Viral Hepat. 2021 Jul 5. doi: 10.1111/jvh.13566.
    PubMed     Abstract available


  398. LOU T, Li B, Xiong P, Jin C, et al
    External Validation of Hepatocellular Carcinoma Risk Scores in Patients with Chronic Hepatitis B Virus Infection in China.
    J Viral Hepat. 2021 Jul 4. doi: 10.1111/jvh.13569.
    PubMed     Abstract available


  399. FARSIMADAN M, Riahi SM, Muhammad HM, Emamvirdizadeh A, et al
    The Effects of Hepatitis B Virus Infection on Natural and IVF Pregnancy: A Meta-analysis Study.
    J Viral Hepat. 2021 Jul 3. doi: 10.1111/jvh.13565.
    PubMed     Abstract available


  400. LIU Y
    Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B.
    J Viral Hepat. 2021 Jul 3. doi: 10.1111/jvh.13568.
    PubMed     Abstract available


  401. LIU Y
    Reply to "Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B" - a reply.
    J Viral Hepat. 2021 Jul 3. doi: 10.1111/jvh.13567.
    PubMed     Abstract available


  402. MCGUIRE FH, Andre K, Bradsher ML, Harrison D, et al
    Willingness to participate in research among black patients with liver disease: A national cross-sectional study.
    J Viral Hepat. 2021;28:982-993.
    PubMed     Abstract available


    June 2021
  403. GIRALDEZ-GALLEGO A, Rodriguez-Seguel E, Pascasio-Acevedo JM
    Optimal hepatitis B vaccination schedule for cirrhotic patients: a still unanswered question.
    J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13563.
    PubMed     Abstract available


  404. KIM HP, Edwards A, Reeve BB, Golin CE, et al
    Symptoms and Functioning Improve after Chronic Hepatitis C Cure as Assessed by the Memorial Symptom Assessment Scale and PROMIS Measures.
    J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13561.
    PubMed     Abstract available


  405. KUMADA T, Toyoda H, Yasuda S, Tada T, et al
    Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis.
    J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13562.
    PubMed     Abstract available


  406. YOO S, Lim TS, Lee HW, Kim JK, et al
    Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B.
    J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13560.
    PubMed     Abstract available


  407. KANG Q, Xu J, Luo H, Tan N, et al
    Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
    J Viral Hepat. 2021 Jun 9. doi: 10.1111/jvh.13558.
    PubMed     Abstract available


  408. NISHIDA Y, Imamura M, Yuji T, Morio K, et al
    Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients.
    J Viral Hepat. 2021 Jun 9. doi: 10.1111/jvh.13557.
    PubMed     Abstract available


  409. DONG Y, Li A, Zhu S, Chen W, et al
    Biopsy-proven liver cirrhosis in young children: A 10-year cohort study.
    J Viral Hepat. 2021;28:959-963.
    PubMed     Abstract available


  410. CHENG D, Han B, Zhang W, Wu W, et al
    Clinical effects of NTCP-inhibitor myrcludex B.
    J Viral Hepat. 2021;28:852-858.
    PubMed     Abstract available


    May 2021
  411. WANG S, Fang S, Liu Y
    The 5-year cumulative incidence HCC development and treatment regimen in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment.
    J Viral Hepat. 2021 May 29. doi: 10.1111/jvh.13553.
    PubMed     Abstract available


  412. BROWN C, Siegele M, Wright M, Cook C, et al
    Injecting network structure determines the most efficient strategy to achieve Hepatitis C elimination in people who inject drugs.
    J Viral Hepat. 2021 May 28. doi: 10.1111/jvh.13554.
    PubMed     Abstract available


  413. RODRIGUEZ-TAJES S, Lens S, Forns X
    Reply to: Optimal hepatitis B vaccination schedule for cirrhotic patients: a still unanswered question.
    J Viral Hepat. 2021 May 28. doi: 10.1111/jvh.13555.
    PubMed     Abstract available


  414. ARSLAN F, Franci G, Nastri BM, Pagliano P, et al
    Hepatitis B virus-induced Hepatocarcinogenesis: A Virological and Oncological Perspective.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13551.
    PubMed     Abstract available


  415. SMITH DA, Bradshaw D, Mbisa J, Manso CF, et al
    Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAA Therapy.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13549.
    PubMed     Abstract available


  416. OHLENDORF V, Schafer A, Christensen S, Heyne R, et al
    Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting- results from the German Hepatitis C-Registry (DHC-R).
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13546.
    PubMed     Abstract available


  417. DUFFELL E, Cortez-Pinto H, Simonova M, Dalgard O, et al
    Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13545.
    PubMed     Abstract available


  418. LIU PC, Chan C, Huang YH, Chen YJ, et al
    Genetic Variants Associated With Serum Alanine Aminotransferase Levels Among Patients With Hepatitis C Virus Infection: A Genome-Wide Association Study.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13550.
    PubMed     Abstract available


  419. KIM S, Powell J, Naugle J, Ricco M, et al
    Patient-Reported Experiences with Direct Acting Antiviral Therapy in an Integrated Model of Hepatitis C Care in Homeless Shelters.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13544.
    PubMed     Abstract available


  420. NANA J, Skaare K, Bosson JL, Leroy V, et al
    EASL-ALEH 2015 algorithm for the use of transient elastography in treatment-naive patients with Hepatitis B: an independent validation.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13548.
    PubMed     Abstract available


  421. MCDONALD SA, Barclay ST, Innes HA, Fraser A, et al
    Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13543.
    PubMed     Abstract available


  422. COMBET C, Bhardwaj N, Hedskog C, Podlaha O, et al
    Hepatitis B Virus Genome Diversity in Adolescents: Tenofovir Disoproxil Fumarate Treatment Effect and HBeAg Seroconversion.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13547.
    PubMed     Abstract available


  423. HUANG PY, Wang JH, Hung CH, Lu SN, et al
    The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients.
    J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13528.
    PubMed     Abstract available


  424. WOLF JM, Pereira VRZB, Simon D, Lunge VR, et al
    Temporal and geographic spreading of hepatitis B virus genotype A (HBV-A) in Brazil and the Americas.
    J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13527.
    PubMed     Abstract available


  425. COWAN E, Hardardt J, Brandspiegel S, Eiting E, et al
    Care cascade of patients with Hepatitis C and HIV identified by Emergency Department screening.
    J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13529.
    PubMed     Abstract available


  426. LEE J, Kim GA, Kim HJ, Cho S, et al
    Tenofovir Disoproxil Fumarate on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Failure to Preceding Treatments: A Nationwide Cohort Study.
    J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13530.
    PubMed     Abstract available


    April 2021
  427. KUMADA T
    Reply to: 'Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis'.
    J Viral Hepat. 2021 Apr 28. doi: 10.1111/jvh.13514.
    PubMed    


  428. CHEN H, Ding X, Liao G, Xia M, et al
    Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non-cirrhotic HBeAg-positive chronic hepatitis B.
    J Viral Hepat. 2021 Apr 26. doi: 10.1111/jvh.13526.
    PubMed     Abstract available


  429. CALVARUSO V, Petta S, Cacciola I, Cabibbo G, et al
    Liver and Cardiovascular Mortality After Hepatitis C Virus Eradication by DAA: data from RESIST-HCV Cohort.
    J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13523.
    PubMed     Abstract available


  430. FIMMEL CJ, Khan MQ, Belopolsky Y, Imas P, et al
    Sustained and cumulative impact of an electronic medical record-based alert on a hepatitis C birth cohort screening program.
    J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13524.
    PubMed     Abstract available


  431. HERNANDEZ C, Trujillo D, Turner CM, Sicro S, et al
    Reaching trans-women in San Francisco for efforts to eliminate hepatitis C.
    J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13521.
    PubMed     Abstract available


  432. YU W, Ji H, Long F, Chen S, et al
    Inhibition of Hepatitis E Virus Replication by Zinc-Finger Antiviral Protein synergizes with IFN-beta.
    J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13522.
    PubMed     Abstract available


  433. ANUGWOM C, Campbell C, Debes JD
    Assessment of subclinical effects of Hepatitis E virus infection in the United States.
    J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13519.
    PubMed     Abstract available


  434. COOPER SL, King WC, Mogul DB, Ghany MG, et al
    Clinical Significance of Quantitative e Antigen in a Cohort of Hepatitis B Virus Infected Children and Adults in North America.
    J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13520.
    PubMed     Abstract available


  435. MOKAYA J, Vasylyeva TI, Barnes E, Ansari MA, et al
    Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations.
    J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13525.
    PubMed     Abstract available


  436. GOUTZAMANIS S, Spelman T, Harney B, Dietze P, et al
    Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs.
    J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13516.
    PubMed     Abstract available


  437. KAMALAPIRAT T, Yingcharoen K, Ungtrakul T, Soonklang K, et al
    Assessing Risk Scores for Predicting Hepatocellular Carcinoma in Thai Patients with Chronic Hepatitis B.
    J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13517.
    PubMed     Abstract available


  438. SHEN DT, Han PC, Ji DZ, Chen HY, et al
    Epidemiology estimates of hepatitis D in individuals co-infected with HIV and HBV, 2002-2018: a systematic review and meta-analysis.
    J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13512.
    PubMed     Abstract available


  439. HARTARD C, Fenaux H, Gentilhomme A, Murray JM, et al
    Variability in molecular characteristics of Hepatitis E Virus quasispecies could modify viral surface properties and transmission.
    J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13513.
    PubMed     Abstract available


  440. WENG F
    Comment on "Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis".
    J Viral Hepat. 2021 Apr 19. doi: 10.1111/jvh.13515.
    PubMed     Abstract available


  441. DZINGIRAI B, Katsidzira L, Matyanga CMJ, Postma MJ, et al
    Progress on the elimination of viral hepatitis in Zimbabwe: A review of the policies, strategies and challenges.
    J Viral Hepat. 2021 Apr 2. doi: 10.1111/jvh.13510.
    PubMed     Abstract available


  442. YAO K, Liu J, Wang J, Yan X, et al
    Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the gray zone.
    J Viral Hepat. 2021 Apr 2. doi: 10.1111/jvh.13511.
    PubMed     Abstract available


  443. ZHANG Y, Xu W, Zhu X, Li X, et al
    The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study.
    J Viral Hepat. 2021;28:592-600.
    PubMed     Abstract available


  444. LEE TH, Chan A, Bryan W, Park L, et al
    Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort.
    J Viral Hepat. 2021;28:630-636.
    PubMed     Abstract available


    March 2021
  445. PERICOT-VALVERDE I, Rennert L, Heo M, Akiyama MJ, et al
    Rates of perfect self-reported adherence to direct-acting antiviral therapy and its correlates among people who inject drugs on medications for opioid use disorder: The PREVAIL study.
    J Viral Hepat. 2021;28:548-557.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.